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Abstract 
 
Malaria is a devastating global health issue that affects approximately 200 million people 
yearly and over half a million deaths are caused by this parasitic protozoan disease. Most 
commercially available drugs only target the blood stage form of the parasite, but the only way 
to ensure proper elimination is to treat the exoerythrocytic stages of the parasite development 
cycle. There is a demand for the discovery of new liver stage antimalarial compounds as there 
are only two current FDA approved drugs for the treatment of liver stage parasites, one of which 
fails to eliminate dormant forms and the other inducing hemolytic anemia in patients with G6PD 
deficiency. In efforts to address the dire need for liver stage drugs, we developed a high-
throughput liver stage drug-screening assay to identify liver stage active compounds from a wide 
variety of chemical libraries with known blood stage activity. The liver stage screen led us to 
further investigate an old, abandoned compound known as menoctone. Menoctone was 
developed as a liver stage active antimalarial, however, the development of more potent 
compounds led to the abandonment of further menoctone research. Our research demonstrated 
that resistant parasites can transmit mutations through mosquitoes, which was previously 
believed to not be possible. Furthermore, we studied a novel genetic marker that may indicate 
potential resistance against malaria parasite infection and the cytotoxic effects associated with 
the disease. Future experiments aim to identify and advance our methods for the elimination of 
Plasmodium exoerythrocytic parasites. 
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Chapter One 
 
Introduction 
 
Malaria – A Health Concern Affecting Mankind for Centuries 
In 2015, the World Health Organization estimated 214 million new cases of malaria 
worldwide and 236,000 to 635,000 deaths resulting from the disease (1). Between 2000 and 
2015, malaria incidence rate has fallen by 37% globally, and 42% in Africa alone. There are five 
species of malaria that cause human parasitic infection: Plasmodium falciparum, Plasmodium 
vivax, Plasmodium malariae, Plasmodium ovale, and zoonotic infection Plasmodium knowlesi. 
Plasmodium falciparum, the most deadly of all malaria parasites, is endemic in Sub-Saharan 
Africa, South East Asia, and the northern parts of South America (Figure 1.1). P. vivax causes 
less severe manifestations, but requires treatment due to relapsing forms. A characteristic trait of 
P. vivax is its ability to lay dormant in the liver as hypnozoites, causing relapsing infections 
months to years after primary parasitemia (2). Malaria transmission occurs exclusively through 
the bite of Anopheles mosquitoes, which are crepuscular or nocturnal insects and thus more 
active after sunset (1, 3). Anopheles mosquitoes prefer to bite humans instead of animals and 
breed in shallow pools of fresh water, such as in rice fields and small puddles after rainfall. 
Transmission relies on climatic conditions, such as rainfall patterns, humidity and temperature, 
which affects mosquito breeding and their survivability. In South East Asia, transmission is 
seasonal, with the peak of malaria occurring right after the rainy season. Even though malaria is 
still a problem in many areas of the world, the parasitic threat was eradicated in United States by 
1951. Successful vector control was achieved through the drainage of swampy areas and the 
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application of an organocholoride known as dichlorodiphenyltrichloroethane (DDT) by the 
Office of Malaria Control in War Areas, which later became known as the Centers for Disease 
Control (CDC) (4). Efforts over the past 15 years towards the elimination of malaria have proven 
that the amalgamation of artemisinin –combination therapy (ACT), insecticide treated bed nets 
(INTs) and indoor residual spraying (IRS) have effectively decrease the global burden caused by 
malaria. Nevertheless, parasites are constantly developing new resistance mechanisms to survive 
the assault from new antimalarials, thus reinforcing the need to continue our efforts and discover 
novel compounds in order to completely eradicate malaria from the world. 
 A Snapshot into Malaria Discovery. Malaria is caused by an obligate intracellular 
protozoal parasite that has plagued scientists and mankind for centuries. Historical documents 
highlight accounts of fevers related to massive floods in ancient Rome Greece, China and Egypt. 
The first accounts of malaria can be traced back to 2700 BC in an ancient Chinese medical text, 
called Huangdi Neijing. This book is also known as the Inner Canon of Huangdi, which 
documented the symptoms of what would later be identified as malaria. In the 4th century BC, 
malaria plagued the Grecians and decimated the city-state populations. Hippocrates (460-377 
BC) was the first physician to describe the paroxysm caused by malaria and categorized the 
different clinical types by the periodicity of the fevers observed (5). Malaria has affected how 
history writes itself by wiping out barracks full of soldiers with one deadly mosquito. However, 
the pathophysiology of the disease and its causes were not comprehended until the late 19th 
century. The parasites were first observed in blood smears of infected patients in 1880 by French 
military surgeon, Charles Louis Alphonse Laveran (1845-1922) while he was stationed in 
Constantine, Algeria. While in Algeria, Laveran performed necropsies on victims who perished 
from an unknown disease. The infected blood samples revealed loads of pigmented bodies and 
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Laveran even described structures representing flagella. The flagella seen by Laveran would later 
be known as the exflagellation of microgametes, but during his time, many did not accept his 
finding immediately. The military surgeon also found evidence of pathological pigments in the 
brain, spleen, and liver of patients who died of malaria. He first named the parasites Oscilliaria 
malariae but over time, the Italian based name of Plasmodium became the genus for malaria (6). 
After Laveran’s death, scientists of the time still had no idea how malaria was transmitted. In 
1897, Ronald Ross (1857-1932) a British military surgeon, identified what would be later known 
as oocysts of Plasmodium falciparum in an anopheline mosquito that fed on an infected patient 
(7). Ross spent two and a half years feeding mosquitoes to infected patients who demonstrated 
fevers, then dissected the mosquitoes looking for flagella. While searching for parasite flagella, 
Ross came across perfectly circular hyaline bodies in the midgut of the mosquito containing a 
few fine granules of black pigment, which he deemed to be identical to plasmodia crescents 
found in the blood. That same year, Giovanni Battista Grassi (1854-1925), Amico Bignami 
(1862-1919) and Guiseppe Bastianelli (1862-1959) described the developmental stages of the 
malaria parasite (8). In 1898, MacCallum observed the developmental stages of avian malaria, 
Plasmodium relictum, in the liver and spleen of infected birds. This observation sparked the 
theory of malaria affecting other animals. By the late 1930s, scientists had proven that all avian 
malaria parasites underwent a multiplication phase in nucleated cells before and after parasites 
appeared in the blood. The full life cycle of human malaria took nearly seventy years to 
elucidate. Even though the advancement of science and technology has come a long way, 
humanity still struggles with the social, economical and health issues brought on by malaria. 
The Life Cycle of the Plasmodium Parasite. The malaria parasite posses fourteen 
chromosomes, five thousand genes and exhibits a complex life cycle with distinct developmental 
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stages. The Plasmodium life cycle involves two hosts; Anopheles mosquitoes are the definitive 
host, where sexual reproduction occurs. The second intermediate host is humans, where asexual 
reproduction takes place (Figure 1.2).  The parasite starts its journey being ejected out of the 
proboscis, a hypodermic needle-like projection, from a female Anopheline mosquito as she takes 
a blood meal. Only a small number of sporozoites endure the trip, but those that survive take 
advantage of the human circulatory system to find the liver. Research has shown that once 
sporozoites reach the liver, circumsporozoite protein (CSP) and thrombospondin-related 
adhesive protein (TRAP) located on the parasite’s surface bind to highly sulfated heparin sulfate 
proteoglycans (HSPG) on the liver in order to start the hepatocyte invasion process (9). 
Sporozoites then invade hepatocytes through resident liver macrophages known as Küpffer cells 
(10). The sporozoite traverses multiple liver cells before settling on one cell to complete its 
development. Within this hepatocyte, the sporozoite will undergo asexual development into a 
liver schizont, containing multiple merozoites. These merozoites will be released into the blood 
stream as a packet called a meresome, where it will burst, releasing the merozoites into its 
victim. As the parasite enters the erythrocytic phase of its life cycle, it will invade uninfected red 
blood cells. The newly invaded red blood cells will house the merozoites as it develops into a 
ring, a trophozoite, and a blood stage schizont. Rings are hardy, non-metabolically active young 
trophozoite stages that have a characteristic “diamond ring” like morphology when stained with 
Giemsa stain. As the parasite increases in size, the “ring” structure disappears and becomes a 
metabolically active feeding parasite, known as a trophozoite. During this time, the parasite 
ingests the host cell cytoplasm and breaks down hemoglobin, releasing toxic free-heme. Since 
free-heme is deadly to the parasite, the protozoan has developed mechanisms to crystallize the 
toxins and form a non-toxic by-product known as hemozoin. The last developmental stage of the 
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erythrocytic life cycle is the formation of schizonts. This nuclear replication process allows for 
the formation of individual merozoites, which upon rupture, go on to invade new uninfected red 
blood cells. Research has demonstrated that the fevers experienced by patients have been linked 
to the synchronous breakdown of infected erythrocytes, which triggers a rush of tumor necrosis 
factor (TNF), causing the periodic fevers (11). During the blood stages of infection, a pre-
determined number of parasites will develop into males, microgametes, and females, 
macrogametes. When an uninfected female Anopheles mosquito takes a blood meal from an 
infected intermediate host, the gametocytes are ingested and continue the sexual stages of the 
parasitic life cycle in the host midgut. Throughout its life cycle, the parasite is primarily in a 
haploid state and only exists as a diploid zygote after the male and female gametes mate in the 
mosquito midgut. Mating occurs when mature microgametes exflagellate and fuse with a mature 
macrogamete. Exflagellation is triggered by an increase in pH, a drop in temperature, and contact 
with xanthurenic acid, which is found in the mosquito midgut (12). Zygotes transform into 
actively motile ookinetes burrow through the midgut wall and reemerge on the basal side of the 
epithelium as oocysts. After 8 to 15 days, depending on the malaria parasite species, each oocyst 
will burst possibly releasing thousands of haploid sporozoites. The number of sporozoites 
contained within each oocyst is dependent upon the parasitic burden of the victim on which the 
mosquito fed. After the oocysts burst, sporozoites are released into the haemocoel and travel 
towards the salivary glands of the mosquito. Although it is still unknown how sporozoite 
migration toward the salivary glands is completed, research has suggested two possible 
mechanisms, first chemotaxis playing a role and second, haemocoel circulation mediation (13-
15). Once housed in the two, tri-lobed salivary glands of the mosquito, the sporozoites are ready 
to continue to infect new victims. 
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Disease Signs and Symptoms: Uncomplicated and Severe Malaria and Malaria in 
Pregnancy. The incubation period for P. falciparum, starting from the time of infection to the 
first onset of symptoms, usually occurs between 8 to 14 days in people with no acquired 
immunity against malaria. However, individuals who have had contact with the deadly parasite 
may experience a longer incubation period. Malaria episodes are highly dependent on the 
individual’s age, immune response, genetics, and previous infections. In areas such as Thailand, 
peak transmission rate is observed immediately following the rainy season, which plays a key 
role in disease severity. In regions of moderate to high transmission rates, young children 
typically experience four to six malaria induced febrile episodes per year (16). Malaria patients 
present with a variety of symptoms and the severity of the disease can range from uncomplicated 
to severe. Uncomplicated malaria describes the classical malaria disease manifestation seen in 
patients. Symptoms characteristic of uncomplicated malaria include, general malaise fever, 
chills, headaches, sweats, body aches, nausea and vomiting. In countries where malaria is not 
endemic, many physicians mistake the symptoms for the common influenza virus or cold. 
However once malaria is suspected, a physical examination by a physician may reveal mild 
jaundice and hepatosplenomegaly. Severe malaria caused by P. falciparum infections is 
characterized by serious organ failure or severe abnormalities in the patient’s blood chemistry. 
Severe malaria signs include cerebral malaria, severe anemia, convulsions, blackwater fever, 
hyperparasitemia, pulmonary edema, hemoglobinuria, metabolic acidosis, hypoglycemia, and 
acute renal failure. The danger P. falciparum infection lies in the sequestration of infected 
erythrocytes to organs such as the brain and the placenta in pregnant women. The accumulation 
of infected erythrocytes in the brain causes microvascular obstructions which blocks blood flow 
leading to ischemic damage and eventually death. As parasites roll along the endothelium and 
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cytoadhere to ICAM-1 receptors, the parasites also release toxins as a byproduct of erythrocyte 
ingestion, which causes inflammation of the brain (17). Cerebral malaria causes the highest 
mortality rates and occurs most frequently in older children. Malaria is also a major issue 
amongst pregnant women. Approximately 24 million pregnant women are affected by malaria 
annually (18). Although it remains asymptomatic for the most part, malaria in pregnancy is a 
leading cause of abortion, stillbirths, low birth weight of the infant, and maternal anemia. P. 
falciparum infected erythrocytes adhere to human host endothelium and its receptors CD36 and 
chondroitin sulfate A (CSA) as a protective mechanism to avoid elimination by the spleen (19). 
Research has found that CSA adhesion is specific to pregnant women as it is rarely observed in 
parasite isolates collected from children, non-pregnant women and men (20). Knob-like 
structures, which are proteins exported to the surface of the infected red cell, displaying P. 
falciparum erythrocyte membrane protein-1 (PfEMP1) help the parasite cytoadhere to the host 
endothelial lining (21). Malaria parasites accumulate in the microvasculature of the placenta, 
disrupting the nutritional exchange between mother and fetus, causing fetal growth retardation 
(22).  
Disease Diagnosis. Diagnosis of malaria may be difficult in areas where malaria is no 
longer endemic. Clinicians may overlook the possibility of malaria as a potential diagnosis and 
or laboratorians may lack the experience with malaria and fail to detect parasites in blood 
smears, but to the trained eye, there are a few methods of detection and clinical diagnosis of 
malaria. The 2015 World Health Organization Methods Manual: Microscopy for the Detection, 
Identification and Quantification of Malaria Parasites recommends microscopic identification of 
the Plasmodium parasite in thick and thin 3%v/v Giemsa stained blood slide smears (23).  
Malaria parasites can be identified by examining a droplet of infected blood on a glass slide, 
 8 
which is smeared thinly and stained with Giemsa stain. Giemsa stain enhances the erythrocytic 
forms to stain bright blue-purple by binding to the malarial parasite and malarial pigment located 
in its cytoplasm (24, 25). Giemsa staining is an inexpensive, rapid and reliable method, allowing 
for not only density determination, but also species identification. Diagnosis of malaria can also 
be achieved by molecular biology techniques involving polymerase chain reaction (PCR) or 
antigen detection through immuochromatographic testing techniques. Antigen detection, also 
known as rapid diagnostic tests (RDT) serves as an alternative to microscopy where microscopic 
diagnosis is not available, mainly in some clinical settings. Food and Drug Administration 
(FDA) approved malaria detection kits detect for several antigens: histadine-rich-protein-2 
(HRP-2) and aldolase. HRP-2 is synthesized and released by trophozoites and immature 
gametocyte stages only in P. falciparum malaria infections, and its presence becomes easily 
detectable as the parasite persists in the peripheral blood. Aldolase is a pan-malarial antigen that 
helps secure a positive identification of malaria infection. Although RDT is approved for malaria 
diagnosis in the United States, the FDA still recommends confirmation by parasites via 
microscopy (3). Malaria identification is also feasible by detecting parasite nucleic acids using 
PCR. This method may be slightly more sensitive than smear microscopy but also demands more 
time to establish a diagnosis of malaria infection. PCR requires sophisticated laboratory tools 
that may not be available in the clinical field setting, but if available, is most useful for the 
confirmation of malarial parasite species. Serology through the use of enzyme-linked 
immunosorbent assay (ELISA) or indirect immunofluorescence (IFA) is also able to help detect 
antibodies against malaria parasites. IFA and ELISA do not detect current infections, rather they 
measure past exposures and infections. 
 9 
Control and Eradication Efforts. Malaria is spread through the bite of the Anopheline 
mosquito and controlling the disease is highly dependent on vector control and drug treatment 
methods. The methods used for decreasing the spread of this parasitic disease have improved 
considerably over the last decade and thus have decreased the mortality rate significantly. 
However, the rise in the development of resistant parasites constantly threatens the control 
efforts implemented (26). Sadly, malaria affects poor areas of the world where the inhabitants 
lack funds to ensure proper drainage and the suboptimal housing conditions allow for the flying 
insects to feed on their victims at night. The warm climate and large amounts of rainfall supply 
optimal breeding grounds for mosquitoes to lay their eggs and without proper drainage, allow for 
the full development to adult mosquitoes. One significant way to control the spread of malaria is 
by eliminating the vector that spreads the disease. In the 1940s and 1950s, malaria was 
eliminated in the United States through the use of 1,1,1-trichloro-2,2-di(4-chlorophenyl)ethane, 
also known as DDT, in homes throughout the southeastern United States. Discovered in 1939 by 
Swiss chemist Paul Hermann Müller, DDT is a powerful colorless, odorless, tasteless, crystalline 
organocholoride known for its unparalleled potency against insects. In conjunction with proper 
drainage, DDT led to the eradication of malaria in the United States. DDT is a persistent organic 
pollutant that is readily absorbed to the soil and sediments, which exposes terrestrial organisms 
to its toxic effects. Due to its lipophilic properties, DDT has a high potential to bioaccumulate in 
predatory birds (27). DDT is toxic to a variety of living organisms, including marine animals and 
has been shown to cause eggshell thinning resulting in the decline of multiple North American 
prey bird species (28). Writings by Rachel Carson, an American marine biologist, exposed the 
potential health concern threats to humans and animals, which led to the nationwide ban on 
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DDT. Since its ban, no other insecticides have been as effective as DDT; however, other control 
efforts have been in use to control the spread of malaria. 
Insecticide Treated Bed Nets (INTs). The use of insecticide treated bed nets is 
an effective method employed for the control of malaria transmission. The WHO public health 
programs set up for malaria transmission control recommend the use of long-lasting insecticidal 
nets (LLINs) to help prevent people from getting bitten by mosquitoes at night. Other programs, 
such as the Centers for Disease Control (CDC) Foundation’s Bed Nets for Children, help make 
bed nets affordable and attainable by purchasing and distributing the treated bed nets in places 
like Kenya and Haiti. Most bed nets are made of polyester, polyethylene or polypropylene 
soaked with pyrethroid insecticides. Pyrethroid insecticides have been approved for use on INTs 
due to its low health risk to mammals but high toxicity to insects, even at low concentrations. 
Pyrethroid based chemicals are stable and resist breakdown unless it is exposed to sunlight or 
washed, but reapplication of the compound provides full protection once again. INTs are used to 
cover beds in endemic areas during the night, which is the peak time for mosquito feeding.  The 
insecticide repels mosquitoes from attempting to feed, which reduce the number of insect bites to 
the person sleeping inside the confines of the net. However, due to lack of resources and 
knowledge to properly care for these nets, continual use results in widened holes, allowing for 
mosquitoes to invade protected areas.  
Indoor Residual Spraying (IRS). Indoor residual spraying (IRS) is an effective 
way to reduce malaria transmission. IRS works by spraying long-acting chemical insecticides on 
the walls and roofs of houses as well as domestic animal shelters in order to kill the adult 
mosquitoes that land on these surfaces. It is important that most of the houses in the area are 
sprayed such that the maximal benefit is attained. By applying insecticides to the surfaces of 
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human and animal living quarters, malaria transmission is reduced by decreasing the life span of 
the mosquito such that it can no longer transmit malaria parasites from person to person and also 
shrinking the density of the mosquito population as a whole. Despite the high efficacy of IRS in 
controlling malaria spread, it is not used in many places around the world partially due to the 
lack of government commitment and financing to sustain the efforts long term. In addition, 
community acceptance and fears of harmful effects prevent the widespread use of IRS. 
 Current Antimalarial Therapies for Blood Stage Infections. Most drugs on the market 
target blood stage infection and disregard liver stage developing forms. Many compounds have 
been discovered and developed over time to treat the asexual stage parasites whose cyclic 
paroxysm causes the febrile episodes seen in malaria victims. Some compounds are natural 
products found on the bark of trees while others are man-made and synthesized in chemistry 
laboratories around the world. Here we have a brief overview of some of the successful 
antimalarial therapies discovered by man used to treat blood stage malaria infection. 
Quinine. First inadvertently discovered in the 17th century, quinine was used to 
treat malaria symptoms as early as the 1600s. Quinine is found as a component of a South 
American tree known as the cinchona (quina-quina) tree. Legend says that there once was a 
Native American who was lost in the Andrean jungle and developed a high fever. He drank from 
a pool of stagnant water where cinchona trees grew from and found the water to be bitter in taste. 
The Native American thought he was poisoned, but soon found to have relief from his fever and 
spread the word amongst his village about the miraculous water. The legend of quinine’s 
discovery spread to Europe and conquerors seeking to find land in the new world also used the 
story to find relief when they developed sudden fevers in the new uncharted territories. Before 
1820, quinine antimalarial therapy was available by grinding up the bark of the tree into a fine 
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powder and mixed into a liquid before being drunk. In 1820, Pierre Joseph Pelletier and Joseph 
Caventou successfully extracted, isolated and purified quinine from the bark of the tree (29). 
Quinine is an extremely basic compound with a high pH that belongs to the aryl amino alcohol 
group. It possesses rapid schizontocidal action against blood stage malaria parasites. The 
compound has no effect against gametocytes of P. falciparum, however, it does kill P. vivax and 
P. malariae gametocytes. Quinine is absorbed quickly by the body and binds to α-1 acid 
glycoproteins tightly (30). It can be found in cerebrospinal fluid (CSF) and readily crosses the 
placental barrier. The half-life of quinine is approximately 11-18 hours and is quickly excreted 
out of the body (31, 32). Even 400 years after the first documentation of Quinine use, it is still an 
antimalarial that is being used to treat pregnant women along with clindamycin in the first 
trimester of pregnancy (33). 
4-Aminoquinolones. World War II brought about times of turmoil not only 
politically, but on the scientific front as well. Soldiers fighting in the trenches of Europe were 
infected with malaria and the supply of quinine rapidly was used up by the military to treat the 
men fighting on the front lines. Research efforts focused on developing an antimalarial that 
would replace quinine. Scientists preserved the quinolone core structure but replaced and or 
altered the methyl side groups to yield new compounds while maintaining or augmenting the 
antimalarial activity. This resulted in the development of the synthetic class of compounds 
known as the 4-aminoquinolones (34).  
Chloroquine. Chloroquine was developed from its parent compound, resochin. 
Resochin was highly toxic to humans, thus it was abandoned soon after its development, but it 
served as a good chemical basis to develop one of the most potent drugs in the treatment against 
malaria. Chloroquine, also known by its brand name Aralen, is a 4-aminoquinolone that was 
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developed at the end of World War II. It is one of the most effective drugs for treating malaria 
because of its ability to treat multiple forms of Plasmodium and it is also cheap to produce. 
Chloroquine interrupts the malaria parasite’s hematin detoxification process in the red blood cell, 
allowing for toxic heme to build up and kill the parasite (35). As the parasite morphs from ring 
stage to trophozoite stage and finally forming schizonts, the parasites consumes and digests 
hemoglobin in its food vacuole and releases large amounts of hematin as a result of digesting the 
red blood cell from the inside out. Since heme is toxic to the parasite, the parasite has developed 
a detoxification process where it polymerizes the heme into non-toxic hemozoin crystalline 
pigment (36). Chloroquine works by binding with hematin in the µ-oxodimer form and adsorbs 
to the hemozoin crystals, which disrupts the detoxification process and thus destroys the parasite 
(37). For the next 40 years, chloroquine was used not only as prophylaxis, but also for the 
treatment of uncomplicated P. falciparum, P. vivax, P. malariae and P. ovale. Unfortunately, P. 
vivax chloroquine resistance has emerged in countries such as Papua New Guinea and Indonesia 
(38). Due to its superior drug activity the CDC still recommends chloroquine as treatment for 
uncomplicated malaria among pregnant women for chloroquine sensitive strains. For 
chloroquine resistant strains, quinine sulfate with clindamycin is recommended (39).  
Chloroquine Resistance. The development of chloroquine in 1934 
changed how the world was impacted by malaria. However, a few decades of heavy use led to 
chloroquine resistance in P. falciparum and P. vivax. The origins of the resistant P. falciparum 
parasites stem from the Thailand-Cambodia border as well as Colombia in the late 1950s (40). 
By the 1960s and 1970s, the resistance had spread to Southeast Asia, India, as well as South 
America. In 1989, the first cases of resistant P. vivax was reported in Papua New Guinea (41). 
Since there was no replacement drug available that was cheap to produce and effective, malaria 
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mortality and morbidity surged in Africa, mostly affecting children (42). As mentioned 
previously, chloroquine affects malaria by preventing the parasite from detoxifying heme and 
allows the toxins to accumulate. Chloroquine-resistant P. falciparum has developed a way to 
survive the onslaught by reducing the accumulation of drug in the digestive vacuole (43). The 
gene identified as Plasmodium falciparum chloroquine-resistance transporter (pfcrt) is 
responsible for allowing chloroquine resistant parasites to survive chloroquine treatment. These 
point mutations allow for the parasite to efflux chloroquine from the intracellular digestive 
vacuole to the outside the cell. There are eight point mutations that have been identified: PfCRT 
M74I, N75E, K76T, A220S, Q271E, N326S, I356T and R371I.The importance of K76T is 
highlighted by recent data published in the New England Journal of Medicine the Journal of 
Infectious Diseases and Molecular Biochemical Parasitology which showed that K76T is present 
in all chloroquine resistant strains and the mutation is seen over a widespread region including 
areas such as Mali, Cameroon, Sudan, and Mozambique (44). In Southeast Asia, once 
chloroquine use was ceased, the K76T mutation decreased in the parasite population and the 
resistant parasites became progressively more sensitive to chloroquine (45). 
Artemisinin-Combination-Therapy (ACT). Currently, artemisinin combination 
therapies (ACTs) are the first line of chemotherapy treatment for those who have tested positive 
for malaria. Typically, an ACT drug is a combination of an artemisinin derivative, such as 
dihydroartemisinin, which has a short half-life and another compound that has a long-half life. 
The rationale behind combination therapy is that the probability of a parasite arising that is 
simultaneously resistant to two drugs with unrelated mechanisms of action is the product of 
individual parasite mutation frequencies multiplied by the total number of parasites exposed to 
the drug (46). Therefore, the likelihood of this occurrence is 1018, showing a billion-fold 
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reduction in resistance probability for combination therapy in contrast to monotherapy (47). 
Artemisia annua also known as qinghaosu, is a complex sesquiterpene lactone natural product 
was isolated from a Chinese sweet wormwood plant in the 1970s and is the parent compound of 
the highly active ingredient found in artemisinin (ART) (48). ART can also be produced in the 
laboratory through partial synthesis from its abundant intermediate, artemisinic acid. Other 
artemisinin derivatives include artemether, arteether, artesunate, and artelinic acid. Artemisinin 
has undergone improvements for both metabolic stability and aqueous solubility by decreasing 
lipophilicity, which has been shown to aid in increasing bioavailability and decrease 
neurotoxicity. Neurotoxicity has only been observed in in vitro neuronal cell cultures; however, 
this undesirable effect has not been demonstrated at efficacious doses in the clinic (49). 
Lipophilicity has been attributed to the severity of the neurotoxicity detected (50). For those who 
have not been affected by malaria and are travelling to endemic countries, they are recommended 
prophylactic treatment prior to their journey. A typical set of chemoprophylaxis drugs used to 
prevent stage malaria include: Malarone, a mixture of atovaquone and proguanil, chloroquine, 
doxycycline, or mefloquine (51). Although we have a small armory of drugs to prevent blood 
stage malaria, they do come with adverse side effects. For example, doxycycline and Malarone 
are not recommended for pregnant women. Research has shown that doxycycline crosses the 
placenta and is found in fetal tissues and also has revealed evidence of embryo and fetotoxicity 
in animal studies (52, 53). Malarone however contains proguanil, a folate antagonist, which 
brings theoretical concerns of increased risk of congenital malformations due to folate deficiency 
in pregnant women. Chloroquine is a 4-aminoquinoline derived from resochin, was one of the 
most effective drugs at treating malaria due to its ability to treat multiple forms of Plasmodium. 
However, chloroquine resistance originally found on the Thailand-Cambodia border threatens 
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the drug’s efficacy against the parasite. Mefloquine, a synthetic quinolone methanol, is a highly 
effective chemoprophylactic drug and can be used by pregnant women, small children and 
infants. However, rapid resistance to mefloquine has been shown as well as neuropsychiatric 
side-effects haunt those undergoing treatment (54).   
Vaccine Development. A successful vaccine against all species of malaria is 
needed for eventual malaria eradication. Over 30 P. falciparum vaccines are being developed 
targeting different stages of the parasite life cycle. RTS,S/AS01 (RTS,S) is one such candidate 
that has been developed through the partnership between GlaxoSmithKline Biologicals (GSK) 
and PATH Malaria Vaccine Initiative (MVI) with the continued support from the Bill and 
Melinda Gates Foundation. Early clinical development efforts also involved collaborations with 
the Walter Reed Army Institute for Research. The vaccine trials enrolled children in sub-Saharan 
Africa from two age categories 6-12 weeks and 5-17 months. The children were randomized in a 
1:1:1 to receive RTS,S/AS01, three doses of RTS,S, followed by 1 dose of control vaccine or 
four doses of control vaccines. The initial three doses were administered monthly, followed by 
the fourth dose at 18 months post-third dose vaccination. The control group was meningococcal 
group C (MenC) conjugate vaccine and was injected as the fourth dose. The children were 
followed for approximately four years. Published results in the New England Journal of 
Medicine showed that after three doses of RTS,S, clinical malaria was reduced by half in 
children 5-17 months of age (55). Final results indicated that vaccination with three-dose primary 
series decreased malaria in children by 28% and 18% in infants by the end of the study (56). 
RTS,S is the first antimalarial vaccine that has passed Phase 3 clinical testing and received 
positive assessment (55). RTS,S/AS01 is a pre-erythrocytic stage hybrid recombinant protein 
vaccine targeting P. falciparum infection. The hybrid polypeptide known as RTS encompasses 
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the P. falciparum circumsporozoite protein (CSP) known to induce humoral (R region) and 
cellular immune (T region) responses and are coupled with the hepatitis B surface antigen 
(HBsAg) (57). The recombinant protein is expressed in Saccharomyces cervisiae with free 
hepatitis B surface antigens to produce virus-like particles. AS01 is the adjuvant used to augment 
the host immunogenic response. The vaccine was designed to trigger an immune response 
against sporozoites as it enters the bloodstream from the mosquito, preventing liver stage 
infection and thus the entire life cycle of the parasite. The only downfall of the vaccine is storage 
conditions, which requires it to be refrigerated at 2-8°C. There are also other sporozoite-based 
vaccines under development that utilize genetically attenuated sporozoites or whole irradiated 
sporozoites that no longer possess disease pathology potential, but are still able to activate the 
host immune response (58). 
 Functions of the Human Liver: Drug Metabolism. The human liver is the largest organ 
of the body. It is a lobed glandular organ located in the right upper quadrant of the abdominal 
cavity in vertebrate animals and plays a vital role in detoxification and metabolic processes. The 
liver has three functions: production and secretion of bile, metabolic activities, and filtration of 
foreign substances and particles in the blood. We will focus on its principle function: drug 
metabolism and detoxification. From the perspective of the human body, drugs and other foreign 
substances usually cause harm and are toxic in nature; hence, the liver filters out these harmful 
substances, neutralizes, and removes them from the body. The process of metabolism typically 
inactivates drugs; however, even after metabolism, some drugs are pharmacologically active. 
The products yielded from drug degradation are known as metabolites. In some cases, the 
metabolites are more potent than the parent compound. A prodrug is an inactive or weakly active 
compound that is bound to an active metabolite and is usually developed to deliver the active 
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moiety more effectively. Drug metabolism occurs through many different chemical reactions 
including oxidation, reduction, conjugation, hydration, hydrolysis, isomerization, and 
condensation. The purpose of drug metabolism is to breakdown molecules into smaller, inactive 
forms such that the body is able to excrete the drug. The enzymes that metabolize drugs are 
present in a variety of tissues around the body, with highest concentration in liver cells.  The rate 
of metabolism also changes from person to person. For example, some people metabolize drugs 
rapidly such that therapeutic effective blood and tissue concentrations cannot be attained, while 
others are extremely slow, where normal doses may produce toxic effects. This variation is due 
to genetic polymorphisms, diseases, disorders, drug, gender, and age. For instance, if an 
individual lacks genetically controlled isoenzymes CYP2C19 and CYP2D6, the person is a poor 
metabolizer because they lack the gene required to metabolize drugs. Medical conditions such as 
hepatic disease and congestive heart failure also affect drug metabolism due to abnormal organ 
function and decreased blood flow to the liver, respectively. Infancy and advanced age affect the 
cytochrome P450 monooxygenase system significantly (59). Infants have underdeveloped 
hepatic microsomal components, while the elderly suffer from significant decreases in hepatic 
blood flow, enzyme activity and liver mass, but both stages of life share the decreased ability to 
metabolize drugs properly. In a normal adult human, drug metabolism usually occurs in two 
phases; however, some drugs may only need to undergo one of the two phases. The first phase 
usually alters the functional groups located on the drug through oxidation and reduction 
reactions, and during phase two, conjugation of the drug to endogenous substances occurs. 
Metabolites that are formed from phase two of the process are more polar in nature and thus are 
more readily excreted by the kidneys and liver. 
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  Drug Metabolism Rate.  When breaking down most drugs, there is a capacity 
limitation for the rate at which the drugs can be metabolized. Normally, at therapeutic 
concentrations, only a small portion of the enzyme’s metabolic active sites are docked with 
compounds and the rate of metabolism increases with increasing drug concentrations present; 
this is known as first order kinetics. In the case of first order kinetics (or elimination) the rate of 
drug metabolism occurs as a constant fraction of the amount of drug remaining in the body. The 
half-life, in terms of drug metabolism is the amount of time it takes for a substance to lose half of 
its pharmacologic activity. However, when the enzyme sites are all occupied, drug metabolism 
rates increase to its capacity limit and the fixed amount of drug is metabolized as quickly as 
possible, this is known as zero-order kinetics. When drug concentrations increase, the rate of 
metabolism shifts from first-order kinetics to zero-order kinetics such that the body can maintain 
maximal drug degradation and elimination rates (60). 
  Cytochrome P-450. Cytochrome P-450 (CYP450) the most important enzyme 
involved in phase one drug metabolism. Cytochrome P450 belongs to the microsomal 
superfamily of isoenzymes that are responsible for the biotransformation of drugs through 
oxidation. Six of the most significant isoenzymes that have been identified are CYP1A2, 
CYP2C19, CYP2C9, CYP2D6, CYP2E1, and CYP3A4. The enzymes are membrane proteins 
containing heme and are located in the smooth endoplasmic reticulum (ER) of a variety of 
tissues, liver being the most abundant site. Extrahepatic metabolism also may occur in the 
kidneys, skin, gastrointestinal (GI) tract and lungs. Research has proven that CYP3A4 has the 
ability to significantly inactivate some orally administered drugs due to the extensive first-pass 
metabolism in the GI tract (59). Cytochrome P450 3A4 and 2D6 play a vital role in malaria drug 
metabolism. Studies have shown that CYP2D6 generates the metabolites of primaquine and is 
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responsible for the therapeutic effects against malaria infection (61). Human CYP 2D6 is highly 
polymorphic and decreased 2D6 activity has been linked to decreased primaquine antimalarial 
activity (62). The biotransformation of the antimalarial praziquantel has been associated with 
human cytochrome P450 3A4 (63). Unfortunately, the exact roles that the enzymes play have not 
been extensively studied. It interesting to note that P. berghei infections in mice, result in a 
significant reduction in total cytochrome P450 content by approximately 56% and decreased 
NADPH cytochrome P450 reductase activity by 32% (64). Uhl et al also demonstrated through 
enzyme kinetic studies and immunoblot analysis that the loss of activity of CYP3A2 in malaria 
infection is due to the decreased CYP3A2 protein expression. 
 
A Brief History of Liver Stage Drug Discovery 
Tropical diseases have been habitually neglected by pharmaceutical industries because 
these diseases usually are confined to underdeveloped parts of the world. This was changed in 
the beginning of the 20th century when wars in tropical zones required western soldiers to fight in 
disease infested countries far away from home. World War I and World War II pushed for the 
discovery of new antimalarials in order to protect the soldiers from the “bad air” disease. 
Unfortunately, most antimalarial drugs to date target the blood stages of infection, ignoring the 
liver stage. Liver stage antimalarial discovery and development have been obstructed by the 
limited number of genetic tools available; a small number of validated targets and difficulties to 
predict gene function (65).  
However, liver stage development is essential to the parasite’s life cycle and disease 
progression, it is important to discover and develop drugs that target both erythrocytic and 
exoerythrocytic stages of the parasite. With the drug-resistance seen on the front lines of the war 
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against malaria, it is also important to develop a drug that is able to block transmission of the 
parasite from the mosquito to the human while still remaining cost effective to mass produce. 
Currently, researchers have developed a murine and human Plasmodium liver model in order to 
test the efficacy of novel compounds on liver forms. These liver models are vital for liver stage 
drug development research because it serves as a pre-clinical screen that studies the new 
compounds and provides scientific proof that supports the therapeutic benefits of these new 
chemotypes. Once these compounds have proven their efficacy in in vitro and in vivo testing and 
meet all the requirements of pre-clinical testing, the drugs continue to clinical trials.  
Rodent malaria: Plasmodium berghei Liver Stage Model. P. berghei is a protozoan 
parasite that causes malaria in rodents. There are four murine Plasmodium species that have been 
described: P. chabaudi, P. vinckei, P. yoelii and P. berghei. P. berghei was originally isolated 
from thicket rats in Central Africa from the Katanga region. Due to a relatively easy infection 
rate and genetic engineering manipulation, P. berghei is favored as a model for studying human 
malaria. Rodent malarias are species specific, thus, it is safe for the human scientist to use 
without worry of contracting malaria. In regards to liver stage drug assay development and 
research, a large amount of sporozoite yield per dissection is necessary to conduct a successful 
liver stage drug assay. However, P. falciparum is unable to fulfill such demand as it has a rate-
limiting step of sporozoites production in the laboratory setting while P. berghei transmits and 
produces abundant quantities of sporozoites. Although the mating process can and does occur in 
the laboratory setting, the successful production of substantial amounts of sporozoites in P. 
falciparum has proven to be very difficult and taxing. In order to conduct successful experiments 
showing drug efficacy in a high-throughput drug assay, millions of fresh sporozoites must be 
harvested at each dissection. Thus, scientists have turned to using sporozoites from P. berghei 
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and P. yoelii as proxies for studying human in vitro and in vivo liver stage development models.  
P. berghei is used as a liver model because they display very similar development to human 
malaria parasite development as well as disease progression, yet it does not suffer from low 
sporozoite production. By using this surrogate, researchers are able to quantify liver stage 
development in hepatocarcinoma cell lines such as HepG2 in microtiter plates (66). This research 
has paved the way for the development of high-throughput drug screens utilizing 384 well plates 
and even 1536 well plates to efficiently test more novel compounds against the Plasmodium 
parasite. Although murine models have allowed scientists to more effectively discover new drug 
chemotypes, rodent malarias are not currently capable of mimicking hypnozoite development 
since none have yet been described. 
  Pamaquine. Pamaquine, also known as plasmochin or plasmoquine was 
synthesized in 1925 and is the first synthetic 8-aminoquinoline (8-AQ) antimalarial that is used 
to treat malaria (67). Preliminary experimental work evaluating toxicity and therapeutic indexes 
was performed by Dr. W. Roehl at Elberfeld laboratories. His hypothesis was based on 
experiments previously performed by Kopanaris, the brothers Sergent and Algiers and Giemsa, 
demonstrating the effects of quinine injections in infected canaries with P. pracox and P. 
relictum, and how the compound rapidly kills the circulating parasites. Roehl injected diluted 
plasmochin solutions into infected birds and also noticed decreasing circulating parasites in the 
avian patient’s blood. Pamaquine is a relative of primaquine, and is typically taken with quinine 
as a cure for P. vivax infections in humans. Studies conducted in 1945 by the Australian Army 
show that pamaquine slowed but did not prevent the development of the pre-erythrocytic stages 
that are responsible for primary attack. However, it did prevent the development of 
exoerythrocytic stages that cause relapse, which suggest that the drug has liver stage activity 
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(68). In the study, 10 Austrian Army volunteers who had no previous malaria infection were 
each fed on by 20 Anopheles punctulactus mosquitoes that were infected with a New Guinea 
strain of P. vivax and then administrated pamaquine. High doses of pamaquine only prolonged 
the incubation period. Unfortunately, due to the similar structure of primaquine, pamaquine was 
highly toxic and caused sudden onset of severe hemolytic anemia in patients who suffer from 
glucose-6-phosphate dehydrogenase (G6PD) deficiency, which led to the abandonment of its 
therapeutic use (69).  
  Primaquine. The development of pamaquine was a springboard for the 
development of a safer and less toxic 8-AQ antimalarial, primaquine. SN-13,272 also known as 
primaquine, is a 6-methoxy-8-(4-amino-1-methylbutylanimo)-quinoline that was first described 
in 1946 by American scientist Robert Elderfield and his colleagues. It was successfully tested in 
World War II on prisoners, American volunteers and American soldiers (70). Although other 8-
AQ antimalarials such as pentaquine and isopentaquine were also developed in the 1940s, none 
produced better efficacy and lower toxicity than primaquine (71, 72). Currently, primaquine 
remains the only drug approved by the United States Food and Drug Administration as an 
antimalarial used for radical cure of P. vivax as well as the solitary treatment to fight against 
relapsing strains of P. vivax and P. ovale (71). The World Health Organization (WHO) also 
recommends this drug to prevent relapse in patients infected with P. vivax especially in areas of 
low transmission (73). The mechanism of action of primaquine is not fully known but the drug is 
believed to interfere with the cellular respiration of the parasite by generating oxygen free 
radicals and deregulating the electron transport (74). Primaquine has three main uses: 
prophylaxis prior to travel, used in combination with a longer acting drug as malaria prevention 
post-travel, and for the treatment of malaria. Generally, it is safe to use in most adults and 
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children. However, primaquine is highly toxic to pregnant women and individuals who suffer 
from G6PD deficiency (75). G6PD deficiency is a sex-linked genetic disorder that increases an 
individuals’ risk towards intravascular hemolysis when treated with oxidizing drugs like 
primaquine (76). G6PD plays a vital role in the oxidative pentose phosphate pathway, where it 
converts nicotinamide adenine dinucleotide phosphate (NADP+) to its reduced form, NADPH. 
NADPH protects erythrocytes from oxidative stress and is also required for the reduction of 
oxidized glutathione (GSH) by glutathione reductase. GSH is a major reducer of hydrogen 
peroxide (H2O2) in cells, thus protecting the cell further from unnecessary oxidative stress. 
People suffering from this deficiency lack the ability to form NADPH, thus decreasing the 
protection for their erythrocytes from oxidative damage meanwhile increasing the amount of 
oxidative stress produced due to their inability to produce GSH (77). It is also believed that those 
who suffer from G6PD have an intrinsic red cell defect that causes the erythrocyte-increased 
sensitivity to hemolysis by a large number of aromatic amino compounds, including 8-AQs and 
its derivatives. The red cell glutathione levels of sensitive cells are lower than non-sensitive cells 
and poisoning caused by the sulfhydryl groups of red cells causes Heinz bodies formation. This 
suggests that there is a defective mechanism that protects GSH in the non-sensitive cells but not 
in the sensitive cells (78). Potentially fatal clinical symptoms of those ingesting primaquine with 
G6PD include: high fever, vomiting, nausea, severe abdominal pain, headache, hemolysis, 
hemoglobinuria, and acute renal failure.  
  Tafenoquine. Currently in Phase II/III clinical trials for the radical cure of P. 
vivax malaria as a one-day regimen, tafenoquine is one of the most potent and promising drugs to 
treat hypnozoites as well as stage five P. falciparum gametocytes (79). The compound is an 8 –
(4-amino-1-ethylbutyl) dimethoxhy-4 methyl trifluoromethylphenoxyl) quinolone succinate also 
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known as WR238605. Possessing a much longer half-life, greater activity against both liver and 
blood stage malaria, and a better therapeutic index when compared to other 8-AQs, tafenoquine 
has potential to replace primaquine as a prophylactic drug. It also has a shorter treatment course 
of a single dose, which practically ensures patient compliance.  In vitro studies demonstrate that 
this compound has gametocidal and sporontocidal activity, which suggests potential transmission 
blocking qualities (80). These studies also show that there is a significant increase in blood and 
tissue schizontocidal activity compared to primaquine, as well as displaying a synergism with 
chloroquine and artemisinin against schizonts. Research shows that tafenoquine accumulates 
within the food vacuoles and inhibits the detoxification of heme to hemozoin by the parasite 
(81). Hemoglobin is digested by the parasite; however this process produces heme, which is 
toxic to the parasite. Malaria parasites have developed a mechanism that converts free heme into 
hemozoin, which is an insoluble pigment that is non-toxic to the parasite. Tafenoquine inhibits 
hematin polymerization by binding to its –oxo dimer, thus preventing the parasite from 
detoxifying its environment and essentially poisoning itself.  Initial clinical trials of oral 
tafenoquine were well tolerated up to 1200 mg as a loading dose, and 600 mg as a single dose. 
Recent studies evaluated the radical curative efficacy of tafenoquine combined with various 
blood schizontocidal drugs administered at human equivalent doses in a modified Rhesus 
monkey-P. cynomolgi model and the data showed that tafenoquine in combination with other 
drugs, such as chloroquine, are effective at much lower doses than those used in prior P. vivax 
clinical trials (79). However, since tafenoquine is an analogue of primaquine, hemolytic anemia 
still affects those patients who suffer from G6PD (82, 83). 
  Atovaquone. Atovaquone is one of the two current FDA approved treatments for 
exoerythrocytic forms of malaria. The compound is a synthetic hydroxynaphthoquinone, an 
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analogue of ubiquinone, with a chemical structure of 3-[4-(4-chlorophenyl)cyclohexyl]-4-
hydroxynaphthalene-1,2-dione. Atovaquone was approved for use in the United States in 1992 
and with combination with proguanil in 2000. The patent for atovaquone-proguanil from 
GlaxoSmithKline expired in 2013. Malaria parasites are affected by Atovaquone due to the vital 
role that pyrimidine biosynthesis plays into the parasite’s survival. Plasmodium species 
inherently have the ability to produce pyrimidines de novo, however, lack the ability to produce 
purines and must rely on scavenging methods to meet the requirements. Atovaquone blocks the 
mitochondrial electron transport at the cytochrome bc1 complex III of the respiratory chain of 
protozoa. Cytochrome bc1 (ubiquinol: cytochrome c oxidoreductase; complex III) has been 
found to be a major drug target for the prevention and treatment of malaria and has a dimeric 
multi-subunit electron transport protein embedded in the inner-mitochondrial membrane (84). 
Three catalytic subunits are present in all bc1 complexes: cytochrome b, cytochrome c1, and the 
Reiske iron-sulfur protein. This complex as a whole transports H+ into the intermembrane space 
through the oxidation and reduction of ubiquinone through the use of a modified Q cycle (85). 
The Q cycle possess two obligatory binding sites known as Qo and Qi sites. The Qo site is where 
ubiquinol is oxidized near the intermembrane space, and the Qi site is where ubiquinone is 
reduced near the mitochondrial matrix (86). P. falciparum cytochrome bc1 is vital to parasite 
survival because oxidized ubiquinone is used by dihydroorotate dehydrogenase (DHODH) in the 
parasite’s pyrimidine biosynthesis pathway (87). Any type of inhibition in the cytochrome bc1 
complex or DHODH pathway leads to parasite death (88, 89). Thus, by binding to the Qo site of 
the cytochrome bc1 complex, atovaquone is able to cease parasite growth by collapsing the 
transmembrane electrochemical potential and thus preventing pyrimidine biosynthesis to occur 
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(90). Unfortunately, atovaquone is unable to treat relapsing hypnozoites, making it a suboptimal 
drug for the current landscape of antimalarial chemotherapies. 
  Endochin. Endochin was first described more than seventy years ago by Salzer 
and colleagues (91). The compound is a 4-(1H)-quinolone that was initially investigated as an 
antimalarial drug against P. cathemerium, an avian malaria affecting canaries (92). Endochin 
targets the same parasite mitochondrial pathway, cytochrome bc1 as atovaquone (93). The initial 
drug caught the attention of scientists due to its ability to treat and prevent sporozoite-induced 
malaria in birds; however, the developmental efforts were soon ditched after it failed to exhibit 
the same results in humans. In recent years, researchers have revisited the drug and developed 
analogues that have been able to show enhanced metabolic stability as well as potent activity 
against drug-resistant parasites.  
 
Current Liver Stage Drug Discovery Research Progress 
Drug compounds that target both blood and liver stage forms are required to reduce the 
morbidity and mortality caused by malaria. Blood stage parasites are normally maintained and 
propagated in culture, however, liver stage only occurs once and parasites must be isolated from 
the mosquito salivary gland and subsequently infected in each liver stage assay well. The long, 
difficult and tedious process is one of the reasons why most drug discovery efforts to date have 
focused their energies on the blood stage forms and ignored the liver stage. Recently, 
collaboration between Novartis-GNF and St. Jude Children’s Research Hospital screened a 
compound library containing 5,697 blood-stage active inhibitors against liver stage parasites. 
The results revealed 229 compounds, which is less than 5% of the library that had a 50% 
inhibitory concentration (IC50) below 1 µM against liver stage parasites (94). Several of these 
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scaffolds belong to the diydroquinazolinones, phenyldiazenylpyridines, piperazinyl methyl 
quinolones, and bis-benzimidazoles classes. One promising lead drug compound is 2-(p-
bromophenyl)-3-(2-(diethylamino)ethyl-2,3-dihydroquinazolin-4(1H)-one. The 50% effective 
concentrations (EC50s) are 0.46 µM and 0.34 µM against liver stage P. berghei ANKA and blood 
stage P. falciparum 3D7 parasites, respectively (95). These molecules have nominal toxicity to 
mammalian cells and will undergo further development. 
 Medicines of Malaria Venture investigated an endochin derivative some years ago. The 
scientists assigned to this project optimized endochin through the use of various in vitro tests that 
compared antiplasmodial activity, mammalian cytotoxicity along with life cycle fingerprint 
profiling for all parasite stages, as well as ex vivo efficacy against P. falciparum and P. vivax 
clinical field isolates. A number of tests were also performed on this group of new molecules, 
including metabolic stability, enzyme inhibition, pharmacokinetics and safety profiling. An 
assessment of in vivo efficacy against blood and liver stages of infection in murine models of 
malaria, as well as chemical design and synthesis of structural analogs were also preformed. The 
research revealed two 4(1H)-quinolone derivatives known as ELQ-300 and P4Q-391 as late lead 
candidates (96). The group demonstrated the antiplasmodial activities through the use of two 
different assays: fluorescence SYBR green method and the [3H] hypoxanthine incorporation 
assay (97, 98). The EC50 values for ELQ-300 and P4Q-391 are 1.3 to 13.6 nM and 3.18 to 32.3 
nM, respectively. ELQ-300 was chosen as a preclinical candidate as it is easy to synthesize, has 
good oral bioavailability, possesses superior antiplasmodial activity against both in vitro and in 
vivo blood and liver stage parasites, exceptional transmission-blocking activity, low 
susceptibility towards developing resistance, and does not show cross-resistance against 
multidrug-resistant strains of Plasmodium. Research showed that this compound targets the same 
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pathway as atovaquone, yet was effective against a clinical isolate that possessed a mutation at 
the Qo binding site of cytochrome b. 
 Characteristics of Ideal Antimalarial Candidate. Malaria affects areas of the world 
that are located in harsh, humid and hot countries where refrigeration and air conditioning may 
not be readily available to most of its citizens. Although these conditions create the perfect 
environment for breeding mosquitoes it becomes a challenge for scientists and doctors battling 
malaria because the climate in malaria endemic countries is not optimal for drug storage and 
preservation. An ideal antimalarial must be stable and not require special care and storage to 
preserve the potency of the drug. The compound must have fast clearance action to reduce the 
initial parasite burden with the ability to be partnered with another compound that has a longer 
duration such that it can clear the lingering blood stage parasites. The hypnozoites of P. vivax 
must also be a target, as eliminating the dormant forms will prevent future relapse of infection. 
Transmission blocking capabilities is another important characteristic of novel antimalarials, as 
preventing the uptake of viable gametocytes or hindering the injection of live sporozoites would 
decrease and eventually eliminate the spread of malaria. The drug candidate of choice also must 
demonstrate clinical safety and efficacy and good oral solubility. There are many suitable drug 
compounds that show low nanomolar efficacy in vitro; however, due to its subpar bioavailability, 
it is not effective when tested in vivo. One of the major hurdles preventing the complete 
elimination of malaria from the world is patient compliance. Many patients come to the clinics 
complaining of their symptoms, receive their first dose of medication and fail to return either 
because they live too far and transportation is an issue or they feel better and do not understand 
the need to return for a subsequent dosing. Due to patient non-compliance, parasite drug 
resistance increases, which then creates another hurdle for drug developers such that new 
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compounds must also lack cross-resistance. Developing a single effective dose drug would solve 
these issues as patients no longer need to return to the clinic for subsequent drug administration. 
A vital characteristic required for the successful development of a liver stage antimalarial is that 
the drug must be affordable. Drug development from discovery through clinical trials to approval 
typically takes a large financial investment and almost a decade of time. Most drugs are sold to 
the masses of people suffering from the condition, which offsets the costs of drug research and 
development. In the case of parasitic diseases however, the cost of developing these drugs will 
not be paid be for by the consumer because most of those affected by the parasites cannot afford 
to do so. It is of upmost importance for the eradication of malaria that antimalarials be 
inexpensive to develop in mass quantities such that all patients can purchase the medication at a 
reasonable price or for pharmaceutical companies to donate the drugs free of charge.  
Need for a High-Throughput in vitro Liver Stage Drug Screening Assay.  The 
discovery and development process for liver stage antimalarials is long and exhausting. As 
mentioned earlier, blood stage parasites are easily maintained and propagated in laboratory 
culture while liver stage sporozoites acquisition is limited, expensive and difficult to obtain. The 
acquisition of optimal hepatocyte lots, sufficient supply and the ability to grow them are equally 
expensive and challenging as well. Currently we are using an inefficient 96 well liver stage drug-
screening assay that requires 80,000 hepatocarcinoma cells and 15,000 sporozoites per well to 
properly screen drug candidates. Including control drugs and testing drugs in duplicate, this 
assay is only capable of screening a maximum of five drug candidates per plate. This is an 
inefficient use of resources and the development of a high throughput drug screen for liver stage 
chemotypes is needed. Such drug-screening assay has not been described at the time of its 
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development, thus the advancement and optimization of such a screen is the focus of this 
research. 
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Figure 1.1. Global Distribution of P. falciparum and P. vivax. A) Global distribution of 
Plasmodium falciparum. P. falciparum affects sub-Saharan Africa, Central and South America, 
India, and South East Asia. B) Global distribution of Plasmodium vivax. P. vivax affects much of 
South East Asia, India, Central and South America, and limited parts of Africa. 
 
* Reprinted from Trends in Parasitology, Volume 22, Guerra CA, Snow, RW, Hay SI, Mapping  
the global extent of malaria in 2005, 353-358, copyright 2006, with permission from Elsevier. 
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Figure 1.2. Life Cycle of Plasmodium. Plasmodium infection initiates when an Anopheles 
mosquito takes a blood meal on the human host, injecting sporozoites into capillaries located in 
the dermis. The sporozoites use the vascular highway to travel to the liver. Sporozoites pass 
through the liver endothelium and invade a hepatocyte. The liver forms develop over the next 6-
10 days into liver schizonts, which are multinucleated forms containing thousands of merozoites. 
At this point, P. vivax and P. ovale form a dormant developmental stage known as hypnozoites. 
These hypnozoites can cause a disease relapse in the future by proceeding to the next step of the 
life cycle. Mature liver forms are released into the blood stream as packets of merozoites known 
as meresomes, which eventually burst and continue parasite blood stage infection. Merozoites 
attach and actively invade into new erythrocytes through the use of rhoptries and micronemes. 
Blood forms develop from rings to trophozoites to schizonts. The blood stage schizonts burst out 
of the erythrocytes and re-invade other erythrocytes. The cyclic replication causes the symptoms  
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Figure 1.2 continued. experienced by patients and yields exponential increase in blood 
parasitemia. After a few days (P. vivax) or a few weeks (P. falciparum), microgametes (male 
gametocytes) and macrogametes (female gametocytes) form from early trophozoites. Here they 
await for a mosquito to uptake the sexual stages into the midgut of the mosquito where they mate 
to form an ookinete. These motile ookinetes traverse the midgut wall and attach to the outer wall 
of the midgut to form an oocyst. Oocysts contain thousands of sporozoites, and travel through 
the mosquito hemolymph to the salivary gland. The sporozoites populate the salivary glands and 
patiently wait to be injected into their next unsuspecting host. 
 
*Reprinted by permission from Macmillan Publishers Ltd: Nature, License # 3876520482180, 
copyright 2015 
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Chapter Two 
 
Development of a High-Throughput Liver Stage Drug Screening Assay 
 
Note to Reader 
 Portions of this chapter have been previously published (Maignan et al 2016, Journal of 
Medicinal Chemistry) and are utilized with permission from the publisher, see Appendix W. 
 
Rationale of Study 
 There are few in vitro high-throughput liver stage drug screening assays described in the 
literature, each possessing unique attributes suited for specific results however, may possess 
different experimental pitfalls. Also, each research laboratory may choose to use different 
hepatic cell lines, parasites and even measure their results at different time points during the 
assay. One such lab has successfully screened 5,375 known bioactive active compounds, and 
identified 37 liver-stage inhibitors with diverse modes of action as demonstrated by time course 
experiments (65). However, the distinctive feature of their drug screen is the addition of drugs 
prior to adding sporozoites. By adding drugs prior to sporozoites, the parasites may be eliminated 
before liver cell invasion can occur and thus; producing false positive results and leading 
scientists to pursue chemotypes that never display liver-stage activity. In order to properly screen 
large libraries of chemotypes effective against all liver stage parasite development stages, a drug-
screening assay must have optimal hepatocyte seeding density, parasite invasion (including both 
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quantity of parasites as well as invasion time), proper drug addition, and the ability to obtain 
parasite viability results. 
 We started by obtaining two different hepatocyte cell lines, HC-04 and HepG2, both of 
which have been used for Plasmodium liver stage research in the past. HC-04 is a human derived 
cell line that has shown to be able to support the complete exoerythrocytic cycle development of 
P. falciparum. However, development of P. vivax liver stages in HC-04 is not as robust (99). 
HepG2 cells proved to be superior for our research purposes due to its robust morphological and 
functional differentiation, the ability to cultivate these cells on a large scale, and most of all, 
detailed characterization of the cell line. HepG2 cells were then seeded at different densities to 
determine the optimal number of cells that would sustain parasite infection and cell-proliferation 
without overgrowth over the 44-hour experiment. Once a proper cell density was established, we 
then dissected salivary glands, disrupted the glands releasing sporozoites and seeded various 
concentrations of parasite in order to determine the perfect amount of parasites needed to 
produce a robust signal for parasite viability. The upper and lower limits for sporozoite seeding 
to yield signal for our drug screen was also determined. We also determined that the use of 
Promega Luciferase Cell Culture Lysis 5x Reagent in conjunction with Promega Luciferase 
Assay Reagent produced the best results for our experiment. 
 
Materials and Methods 
 Hepatocyte Culture. Frozen HepG2 hepatocellular carcinoma cell line, originally 
derived from a 15-year old Caucasian male, was obtained from ATCC (American Type Culture 
Collection, Manassas, VA, USA) Lot# 59947519. All cells were cultured in a humidified 5% 
CO2 mixed gas incubator at 37°C. The treated surface required for cell adhesion and propagation 
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was rat tail-1 collagen coated 75cm2
 
vented flasks (BD / Corning life Sciences, Corning, NY, 
USA).  The media required for cell maintenance contains: Eagle’s Minimum Essential Medium 
(American Type Culture Collection, Manassas, VA, USA) with 10% heat inactivated certified 
fetal bovine serum (Invitrogen / Life Technologies / Gibco, Grand Island, NY, USA), 1% L-
glutamine (Fisher Scientific / Thermo Fisher Scientific / Grand Island, NY, USA) additional 
supplement, and 1% Penicillin-Streptomycin 10,000 U/ml (Fisher Scientific / Thermo Fisher 
Scientific / Gibco, Grand Island, NY, USA). Cells were cryopreserved in Cell Freezing Medium 
– DMSO 1x (Sigma Aldrich, St. Louis, MO, USA). Cryopreserved cells were thawed according 
to manufacturer’s instructions and cultured with media described above.  Cultures receive media 
change within the first 24 hours post-seeding from cryopreservation stock and media renewal 
every third day. TrypLE Express (Invitrogen / Life Technologies / Gibco, Grand Island, NY, 
USA) was used for subculturing as well as seeding of hepatocytes for experimental purposes. 
Animals and Parasites. All mice used in these experiments were female BALB/c mice 
(the average weight was approximately 18g) obtained from Harlan (Frederick, MD). The 
transgenic P. berghei line 1052 Cl1 (Pb 1052 Cl1) used in the liver stage assay was obtained 
from C.J. Janse at Leiden University. This line was generated from the reference clone of ANKA 
strain c1115cyl and was designed to express a green fluorescent protein (GFP) and firefly 
luciferase (100). Pb 1052 Cl1 has two copies of the GFP-luc integrated into its genome. One 
copy is under the control of a constitutively expressed eef1aα promoter, and the other is under 
the control of an ama1 promoter (100, 101). This study was conducted in compliance with the 
Guide for the Care and Use of Laboratory Animals of the National Research Council for the 
National Academies. The protocol was approved by the University of South Florida Institutional 
Animal Care and Use Committee. 
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Mosquito Rearing. Anopheles stephensi was obtained from the Kim Williamson 
laboratory from Loyola University (Chicago, IL). The Kyle lab mosquito protocol is an adapted 
and optimized version of the mosquito rearing protocol obtained from the Williamson lab, as 
other protocols we tried failed to produce healthy mosquitoes. The materials required for the 
rearing of healthy A. stephensi include: Crystal natural spring water, tweezers, mosquito zapper, 
paper towels, bleach, bleach bucket, Wattman filter paper, Millipore filter, larval pans and pan 
covers, as well as Tetramin baby fish food. All adult mosquitoes are kept on a 10% sucrose 
solution infused into cotton ball pads, which are changed twice a week. On the first day, adult 
females (4 to 5 days old) are blood fed on an aestheticized Balb/C mouse for approximately 20 
minutes. Nothing is done on the second day. On the third day, an egg collection cup is placed 
inside the blood fed cage. The fourth day, also known as larval day zero, the egg collection cup 
is removed using a cap and mosquito zapper. All dead mosquitoes are picked out with a set of 
ethanol-treated tweezers and any live mosquitoes trying to escape were electrocuted.  A specially 
designated A. stephensi Millipore filter with Wattman filter paper is set up on a vacuum system 
to collect the eggs. The empty used egg cup is immediately submerged into a bleach bucket and 
10% bleach solution is used to treat all mosquito forms. The eggs are then rinsed with 1% bleach 
solution using distilled water. The bleach treated eggs are rinsed three times or more with 
distilled water to remove excess bleach. It is important to rinse off all of the bleach as any traces 
of bleach can kill the young first instar larvae. Freshly ethanol-treated and dried tweezers are 
used to place filter paper with clean eggs into a larval pan pre-filled with one liter of Crystal 
Natural Spring Water (Lakeland, Florida, USA). All larval pans are appropriately labeled to keep 
track of which cycle of mosquito larve they belong to. On day five, larval day one, a very small 
amount of Tetramin Baby fish food is added to the pan of eggs. The addition of food triggers the 
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hatching of first instar larvae from the eggs, which are slightly bigger than the size of a pin tip. 
On day six, larval day two, the filter paper left from egg collection is removed using ethanol-
treated tweezers. A little bit more of the Tetramin baby fish food is also added on this day. The 
next day, day seven, larval day three, one pan of first instar larvae is split into three pans with 
one liter water per pan. Larval density should be around 100-200 larvae per pan.  A slightly 
larger amount of food is added to each pan. The amount of food added is still is a small amount, 
but a little more than day six. On day eight, larval day four, only a little bit more food is added to 
each pan. On day nine, larval day five, depending on larval size and water quality, the pan can 
either receive food or can be split if the larvae are still very small. In addition, a little more food 
is also given in relation to the previous days. However, if the water appears yellow or not clear 
and has a slight odor, the second instar larvae must be split into more pans and have more water 
added to each pan up to one liter and food must be administered. Also, if the density of the pans 
is higher than 100-200 larvae per pan, the pans must also be split. Day 10, or larval day 6, is 
considered a rest day in between splitting and only adding of food should be required. Days of 
rest in between splitting and larval manipulation are important, as frequent manipulation of 
mosquito larvae can cause growth retardation at this sensitive stage. Splitting the pans and 
adding food is continued until day 12 and the larvae should not be overfed, or they will become 
ill and start decomposing, which will affect the health of the rest of the pan. On day 12, the 
larvae should be filtered and fed to maintain health and size. Days beyond 12 are splitting and 
feeding days again until the mosquitoes start to pupae. As pupae form, they must be removed 
before they transition into adult mosquitoes. The first few days are manageable to handpick the 
pupae daily; however, with each passing day, more pupae will form and thus we need to use the 
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filter flask method to collect massive amounts of pupae. All pupae are placed in labeled metal 
cages and adult mosquitoes are allowed to feed on 10% sucrose pads. 
  Filter Flask Method. The filter flask method is used for the collection of large 
numbers of formed pupae before the mosquitoes emerge as adults. The pupae are filtered using 
an ultra fine sieve poured into a bleach bucket and subsequently collected into a larvae pan. The 
collected pupae are then poured into an Erlenmeyer flask using a funnel. Since pupae of A. 
stephensi prefer to float to the top of their watery home, they will float to the top of the 
Erlenmeyer flask. We then quickly pour out all the pupae into a pupae-collection cup and put the 
rest of the larvae back into a larval pan where straggling pupae are individually handpicked. 
When collecting pupae or filtering any sort of mosquito larvae, it is extremely important to 
observe if any first, second and small third instar larvae escape through the sieve. The dirty and 
used water must be then filtered through an ultra fine sieve to collect any smaller larval or egg 
forms to prevent their escape into the environment. As A. stephensi is a non-native and invasive 
species capable to transmit malaria, it is of upmost importance that we are extremely cautious 
when handling these live mosquito larvae as well as the adults, such that we prevent the escape 
of any mosquitoes into our atmosphere. 
Mosquito Infections and Sporozoite Production. P. berghei luc ANKA parasites were 
obtained from cardiac puncture from infected BALB/c mice (EnVigo Laboratory, Indianapolis, 
IN) and injected into the intraperitoneal (IP) cavity of non-infected young female BALB/c mice. 
Parasitemia was monitored through tail vein blood smear bi-weekly. Once the parasitemia 
reached 3-5%, the mice were anesthetized with a mixture of xylazene (10 mg/kg) and ketamine 
(100 mg/kg), and placed on cartons of 100 3-4 day-old, native female Anopheles stephensi 
mosquitoes. The mosquitoes were allowed to feed for approximately 30 minutes. After feeding, 
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the mosquitoes were maintained on 10% sucrose inside environmental chambers at 22°C. On day 
10 post-exposure (PE), 20-50 mosquitos were checked for midgut infection through the 
visualization of oocysts on the midgut. On day 21 post-exposure (PE), infected salivary glands 
were dissected (Figure 2.1).  
Midgut Dissections for Oocyst Quantification and Sporozoite Yield Estimation. A 
small sample of mosquitoes was placed into -20°C for five minutes for anesthetization. 
Mosquitoes were sprayed with ethanol and subsequently with 1x phosphate buffered saline 
(PBS) and kept on ice. Multiple 50 µL droplets of PBS were placed on a slide and mosquitoes 
were picked up by the proboscis and laid on the puddle of PBS. A dissection needle pierces the 
thorax of the mosquito as tweezers gently pull from abdominal segment IV down towards the 
cercus. This exposes the malpighian tubules, which are attached to the posterior portion of the 
midgut. Midguts are carefully picked up with dissection needles and placed into a pool of 
mercurochrome solution and allowed to sit for 15 minutes for staining of oocysts. Samples are 
then inspected under 20x light microscopy for oocyst infection. Oocysts are quantified by 
counting the number of oocysts seen and sporozoite yield estimation is based on the number of 
infected midguts as well as the infection grading. Midguts are graded by the following scale: 0-
50 oocysts receives a +; 51-100 oocysts receive a ++; 101-150 oocysts receive a +++, 151-200 
oocysts receive a ++++; and greater than 200 oocysts in a midgut receives a +++++. Midgut 
dissections provide a good estimate of mosquito infection; however, results are not indicative of 
sporozoite burden and thus unable to predict yield. 
Aseptic Mosquito Salivary Gland Harvesting. Cartons of infected mosquitoes that had 
been infected 21 days prior are removed from the 18°C incubator and placed in a -20°C freezer 
for five minutes. Mosquitoes are then removed from their secured cartons and put in a petri dish 
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and placed on ice. Each mosquito was individually washed using 70% ethanol, wash buffer 
containing a mixture of 0.1% Penicillin-Streptomycin (10,000 U/ml) (Invitrogen / Gibco, Grand 
Island, NY, USA) and 0.01% fungizone (Invitrogen / Gibco, Grand Island, NY, USA) in 2 ml of 
PBS (Invitrogen / Gibco, Grand Island, NY, USA) and finally rinsed in 1x PBS (Invitrogen / 
Gibco, Grand Island, NY, USA). Mosquitoes were laid on gamma-irradiated alcohol prep wipes 
(Sax Pax) inside petri-dishes, which were kept on ice until dissection. Sterilized glass slides were 
placed under a dissection microscope on which approximately 50 µL of dissection buffer was 
placed in eight different locations for mosquito dissection. A pre-washed mosquito was placed in 
the pool of dissection buffer and dissections commenced. In order to harvest a salivary gland, a 
pair of fine tweezers was placed behind the eyes of the mosquito and gently pulled while a 
dissection needle would gently apply pressure to the thorax. Once the head of the mosquito 
detaches from the thorax, a pair of tri-lobed, clear yet glistening glands appear near the head of 
the mosquito, which are the salivary glands. The glands must be carefully removed from the 
head without breaking the delicate sacs and placed in sterile, low-retention Eppendorf tubes that 
are pre-filled with 50 µL of Schneider’s insect media (Sigma-Aldrich, St. Louis, MO). The 
collection tube filled with salivary glands is kept on ice until all mosquitoes are dissected or the 
two-hour time limit is reached, whichever is completed first. The glands were pelleted and 
sporozoites were then released by manual disruption of salivary glands by pipetting vigorously 
with siliconized pipet tips. Sporozoites were diluted 1/10 and counted. Mice were humanely 
euthanized following approved IUCAC protocols. 
Drug Screening Assay. Figure 2.2 illustrates the overall process for the liver stage drug-
screening assay. Hepatocytes were counted in a hemocytometer and seeded 24 hours prior to 
experiment start time at an optimized density of 17,500 cells per well in a 384-well rat tail-1 
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collagen coated plate (Becton Dickson, Franklin Lakes, NJ). Cells were seeded using the Tecan 
Freedom Evo robotic system at 50 µL per well. Cell seeded plates were visually inspected under 
an inverted microscope prior to starting mosquito washing and dissections in order to ensure cell 
viability and quality. Cartons filled with infected mosquitoes were anesthetized by freezing the 
cartons at -20°C for five minutes. Mosquitoes were individually washed using 70% ethanol, 
wash buffer, and finally rinsed in PBS. Refer to mosquito infections, sporozoite production and 
harvesting for dissection techniques. Sporozoites harvested were diluted and counted in a 
hemocytometer and then added at an optimized 4,000 sporozoites per well (65) and placed into 
37°C. After a three-hour incubation at 37°C, media was removed and drugs were added to their 
respective wells. Drug candidates from the Manetsch laboratory (Northeastern University, 
Boston, MA) were sent to the University of South Florida and dilutions were created in-house in 
a non-treated, sterile mother plate (Thermo Fisher Scientific, Pittsburg, PA) and all chemotypes 
were tested at three-fold dilution factor with decreasing dosage with each subsequent well. Pre-
stamped drug plates were sent from St. Jude Children’s Research Hospital (Memphis, TN) to test 
their blood stage active drug candidates. A 44-hour incubation period yields our end point where 
we lysed the cells with Promega Cell Lysis Reagent Buffer and added Promega Luciferase Assay 
Reagent (Promega, Madison, WI). This catalyzes the firefly luciferase reaction by reacting 
luciferin with adenosine triphosphate (ATP), creating luciferyl adenylate and PPi. Luciferyl 
adenylate and oxygen then react to yield oxyluciferin, adenosine monophosphate (AMP) and 
light. The amount of light emitted, which is read by the Perkin Elmer EnVision system, indicates 
parasite viability. If the parasite is affected by the drug and thus is not longer viable, then the 
luciferase signal will no longer be emitted, thus determining the viability of the sporozoites after 
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drug treatment. The half maximum inhibitory concentration (IC50), determined from the 
generated growth curves, was and used to evaluate liver stage antimalarial compound efficacies. 
 
Results  
 P. berghei liver stage protocols were gathered, reproduced, and updated in our lab to gain 
handling experience and knowledge on hepatocyte cultures, mosquitoes, salivary glands, and 
sporozoites. Preliminary experiments performed to confirm specific surface treatments would be 
suitable for long-term hepatocyte culture. We tested multiple surface treatments such as poly-D-
lysine, poly-L-lysine, and rat-tail collagen I to determine whether HepG2 cells preferentially 
adhered to a specific surface treatment. HepG2 cells did not adhere to poly-D-lysine or poly-L-
lysine very well; however, when seeded on rat-tail collagen I, HepG2 cells proliferated and 
produced a confluent monolayer. The use of TrypLE Express Enzyme (Gibco, Thermo Fisher 
Scientific, Grand Island, NY) instead of the tradition porcine derived trypsin-EDTA to remove 
cultured cells proved to be gentler on cells and removed HepG2 from collagen surfaces faster, 
reducing the time for removing cells from 15 minutes to seven minutes.  
 Mosquito Feeding Optimization. Traditionally, our labs feed infectious blood to five-
day-old adult, female Anopheline mosquitoes. A recent study published in Malaria Journal using 
avian malaria parasite, Plasmodium relictum and its natural mosquito vector Culex pipiens, 
reported older mosquitoes are significantly more resistant to Plasmodium infection than their 
younger counterparts (102). However, their findings are reversed if older mosquitoes have 
previously taken a non-infected blood meal. We first fed P. berghei luc ANKA infectious blood 
to five and six-day-old mosquitos. Midgut dissections revealed an average infectivity of 72.8% 
with an average midgut score of +++. Five-day-old mosquitoes produced more sporozoites than 
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six-day-old mosquitoes, averaging 11,032 sporozoites per mosquito and 3,129 sporozoites per 
mosquito respectively. Next we fed three and four-day-old mosquitoes and found substantial 
increase in both sporozoite production and development. Three-day-old mosquitoes averaged 
79.3% midgut infection with a score of ++++ and produced an average of 13,503 sporozoites per 
mosquito. Although three-day-old mosquitoes produced decent infections as well as sporozoite 
yield, an issue we encountered was feeding these young mosquitoes. Four-day-old mosquitoes 
yielded a midgut infectivity average of 70% and produced on average 68,839 sporozoites per 
mosquito. During our studies, we observed that four-day-old mosquitoes readily fed on 
anesthetized mice while approximately half the number of three-day-old mosquitoes were 
interested in taking a blood meal. These studies were essential during development of protocols 
for mosquito feeding and sporozoite harvesting for the high-throughput liver stage drug assay 
(Table 2.1). 
Hepatocyte and Sporozoite Optimization. Successful liver stage drug assays require a 
proper seeding density for hepatocytes such that a thin monolayer of cells covers the bottom of 
the well. We determined that seeding density of 17,500 hepatoma cells were required to make 
the appropriate monolayer of cells stretching across the optically clear glass plate bottom with 
dimensions 127.76 mm length by 85.48 mm width. Seeding 24 hours prior to mosquito 
dissection and sporozoite addition gave ample time for the cells to adhere and produce a 
confluent monolayer. Seeding densities higher than 17,500 cells resulted in cellular overgrowth 
at the end of the 48-hour drug assay, decreasing cell viability and increasing cellular detachment 
from the collagen coated surface.  
With confluent cultures, invasion is dependent on sporozoite numbers. Since only 1% of 
liver cells typically become infected by sporozoites (94), we needed to develop a robust drug 
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assay with sufficient sporozoite invasions events. Initially we seeded 4,000 sporozoites per well 
and observed robust luciferase signal from the parasite. The lower and upper limits of sporozoite 
seeding densities were determined to be 3,500 and 7,000 sporozoites, respectively. Seeding 
sporozoites at a density lower than 3,500 sporozoites per well yielded negative results and above 
7,000 sporozoites yielded an over saturation of signal for the well size.  
Reproducibility and Validation of Drug Assay Data. Gold standard drugs such as 
atovaquone that have established IC50 values for both blood and liver stages were used as 
controls to demonstrate the accuracy of our high throughput liver stage drug assay. As expected, 
atovaquone was active against liver stage parasites and produced an average IC50 of 0.28 ng/ml 
(1.42 nM) with an r2 value of 0.99. We then chose one of our leading chemotypes that possesses 
low nanomolar efficacy to be tested repeatedly, known as ICI56,780. In our liver stage assay, 
this compound produced an IC50 value of 0.02 ng/ml (52 pM) on three different, separate 
experimental runs all resulting with r2 values >0.98. Extremely stringent statistical analysis, 
known as z-factor  (Z`) was calculated for our liver stage drug assay. Z` for atovaquone for trials 
one, two and three were 0.131, 0.409, and -0.482, respectively. The Z` for ICI56,780 trial runs 
were 0.340, 0.353, and 0.684, respectively (Figure 2.3b). Kruskal-Wallis one-way ANOVA 
statistical analysis comparing the different trial runs of ICI56,780 against one another showed 
that there were no significant statistical differences detected. Another Kruskal-Wallis one-way 
ANOVA statistical analysis comparing the different trial runs of atovaquone against one another 
showed that there were no significant statistical differences detected as well. This indicates that 
the dose responses were precise and valid results.  
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Applications of HTS Liver Stage Drug Assay. The robust and reliable liver stage drug 
assay results drew interest of other malaria groups to send their compounds for liver stage 
activity testing. The assay we developed screened many different drug classes including 3-
phenyl-4(1H) quinolones (P4Q), natural products, and 7-(2-phenoxyehoxy)-4(1H)-quinolone 
(PEQ), and diaminonaphthoquinones (DANQ). Overall, the liver stage assay has screened over 
2,000 compounds from our collaborators at the Manetsch laboratory (Northeastern University, 
Boston, MA), St. Jude’s Children’s Research Hospital (Memphis, TN), and University of Central 
Florida (Orlando, Florida). Figure 2.2 illustrates a handful of the most active compounds that we 
have tested for our collaborators. The majority of the compounds tested received r2 values >0.95, 
with many compounds, demonstrating r2 values >0.98, and some receiving r2 values of 1. Any 
compounds tested that received an r2 value <0.90 were retested in the liver stage assay to 
determine whether the coefficient of determination was due to poor solubility issues.  
 Screening for Liver Stage Active Compounds: Manetsch Laboratory. Due to 
the limited arsenal of drugs active against malaria, scientists have been working on optimizing 
old antimalarial agents or drugs to evaluate their physicochemical properties (103, 104). Previous 
studies by Manetsch, Kyle, Guy Ward and O’Neill have demonstrated extensive optimization 
procedures can be performed to decrease the problems found with the quinolone compound class 
(105-107). Chemists at the Manetsch Laboratory (Northeastern University, Boston, MA) used 
structural activity relationships (SAR) to manipulate the substituents on a series of 4(1H)-
quinolones to evaluate how these changes affect the activity of the compound. The original 
compound, ICI56780, labeled 6b, used different techniques such as Suzuki Miyaura cross 
couplings to enhance the antimalarial compound’s activity. The chemists also explored the 
optimal length and the election donation or withdrawal effects of the alkyl group in the 6-
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position by varying its length and synthesizing a small set of 4(1H)-quinolones with electron 
donating or electron withdrawing groups (108). Our liver stage assay played a role in the study 
by testing the different chemotypes Manetsch’s group created. The original compound was found 
to have excellent in vitro liver stage activity with an EC50 of 52.0 pM. Removal of 6-butyl or 7-
(2-phenoyxethoxy) group maintained subnanomolar liver stage activity, but slightly decreased 
potency against blood stage parasite forms. Potency was severely affected when ester 
functionality in the 3-position was removed, dropping liver stage activity to 5.82 nM. Attempts 
to increase metabolic stability of 6b by replacing one of the oxygens in the 7-(2-phenoxyethoxy) 
moiety with a methylene unit demonstrated an 18-fold decrease in activity as compared to its 
reference compound. Shortening the length of the alkyl chain linker in hopes to improve stability 
also showed a decrease in liver stage activity. Lastly, phenyl, chloro, and fluoro functionalities 
were substituted in the 7-position to examine the electronic and steric effects, and these 
chemotypes lost all antimalarial activity. Overall, our liver stage assay demonstrated that 7-
phenoyxethoxy-substituted 4(1H)-quinolones demonstrated the most potent liver stage activities 
with low-nanomolar to sub-nanomolar EC50 values (108). 
  Screening for Liver Stage Active Compounds: St. Jude Children’s Research 
Hospital. Our collaborators at the Kip Guy laboratory at St. Jude’s Children’s Research Hospital 
(Memphis, TN) sent blood stage active compounds to be tested for liver stage activity. Many of 
the natural and synthesized compounds came from different vendors and academic research 
institutions, including but not limited to Enamine (Enamine Ltd., Monmouth Jct., NJ), University 
of Mississippi (University, MS), and SRI (Southern Research Institute, Birmingham, AL). Our 
HTS liver stage screened over 1,700 compounds and 20 active compounds were identified to 
have both blood and liver stage activity. A handful of the hit compounds we found are described 
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here. The majority of compounds tested belonged to the DANQ family of compounds. The 
blinded study revealed chemical scaffolds possessing low EC50 values, which are comparable to 
our positive control drug, atovaquone. We used atovaquone because affects of the drug on 
parasites are observed at nanomolar concentrations. Three drugs identified on plate number 
999000328736, and named SJ 1, SJ 2 and SJ 3 demonstrated nanomolar EC50 values of 288 nM, 
32 nM, and 512 nM respectively. Three other compounds found on plate number 999000328767 
known as SJ 4, SJ 5, SJ 6 displayed nanomolar half maximal effective concentrations of 15 nM, 
24 nM and 61 nM. One natural compound known as SJ 7, identified on plate 99900335628 
showed an EC50 value of 107 nM. Scatter and box plots analyzed the data and are shown in 
figure 2.4. Scatter plot of activity were normalized, raw activity at 100 indicates 100% growth 
inhibition and zero raw activity represented 100% parasite growth. An algorithm was used to 
illustrate the dose response curves of each active compound, denoted by blue dots. The box plot 
of activity values was created for quality control purposes and illuminates the robustness of the 
data. All active compounds tested fall within in the black box located in the middle. As seen 
here, the positive (green) and negative (red) controls are very far apart and thus do not over lap. 
The confidence intervals also do not overlap and z-prime is  > 0.5, showing robust data.  
 Though there were many compounds tested, and the majority of them were not active against 
liver stages, we identified a large group of approximately 20 chemotypes that had significant 
liver stage activity. These compounds underwent further optimization and developmental 
processes to test whether the chemotypes are suitable to continue onto clinical trials. 
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Discussion 
 Development and Optimization of a High-Throughput Liver Stage Malaria Screen. 
To date there has been a lack of a high-throughput drug assay system that effectively tests liver 
stage parasites against blood stage active compounds. Compared to blood stage research, 
malaria’s liver stage research lack the molecular and genetic tools needed to better understand 
this stage of the parasite’s development. Many of the drug assays developed waste lots of 
materials and are not an efficient use of resources. The main issue hindering liver stage drug 
development efforts is the requirement to harvest fresh parasites. Presently, parasite production 
and harvesting limitations, especially for P. falciparum, effectively limits the ability to screen 
large chemical libraries. Our study developed a high-throughput, high efficiency, and low waste 
liver stage drug-screening assay that recapitulates liver stage infection by utilizing luciferase-
expressing P. berghei with human liver cells in a 384-well plate. The assay uses the same 
amount of materials as a 96-well plate assay, however yields more than six times the amount of 
compounds tested. Both the carcinoma cell line and sporozoites we used were well characterized. 
P. berghei luc ANKA expresses luciferase, which allowed us to monitor the viability of the 
parasites. During our studies we concluded that the optimal age for feeding mosquitoes with 
infected blood was four-day-old female mosquitoes. Younger mosquitoes seemed to not be 
interested in taking a blood meal soon after emergence from pupae stages and older mosquitoes 
(six-day-old mosquitoes) demonstrated an increase in mortality rate and typically did not survive 
to day 21, sporozoite-harvesting day.  In addition, we optimized the ratio of hepatocytes to 
sporozoites per well and calculated that 17,500 cells to 4,000 sporozoites was the best ratio for 
liver stage infection, producing robust results without waste of precious, limited materials. The 
lower limit of sporozoite seeding without affecting the results of the drug assay was 3,500 
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sporozoites per well. Seeding a well with less than 3,500 sporozoites per well, demonstrated poor 
to no infection, and thus no luciferase activity. With these parameters optimized, we designed 
our drug assay to have minimal amounts of media changing frequency, as it has been shown that 
changing media frequently in extremely small volumes negatively affects the drug assay results 
by disrupting and removing the infected cells.  
 Establishment and Impact of HTS Liver Stage Screening System. Developing a high-
throughput liver stage assay requires the ability for this system to be accurate and reliable. In 
order to validate the reliability of our HTS assay, atovaquone, was tested in the liver stage assay 
multiple times and the dose response results from the different runs were compared to each other 
as well as to previously reported results by other groups. The IC50 curves obtained for 
atovaquone demonstrated tight dose response curves and low nanomolar potency (IC50=0.28 
ng/ml = 1.42 nM) with high coefficient of determination values, all r2 >0.97 (Table 2.2 and 
Figure 2.3a). As extra validation, ICI56,780, a highly potent liver stage compound was tested in 
the liver stage assay. The results showed tight IC50 curves with sub-nanomolar concentrations 
(IC50 = 0.02 ng/ml = 52 pM) and high r2 values (r2 >0.98) (Table 2.2 and Figure 2.3a).   
Statistical Analysis for the Validation of HTS Liver Stage Screening System. 
Extremely stringent statistical analysis method known as z-factor (Z`) was performed on the 
different trial runs for both atovaquone as well as ICI56,780 (Figure 2.3b). Z-factor is a measure 
of statistical effect size. The creator of Z`, Zhang et al, generated the stringent statistical analysis 
for the use in high-throughput screening to compare and evaluate the quality of the assay, and 
can also be used to help optimize and validate HTS assays (109). The coefficient takes both the 
dynamic range of the signal emitted by the assay as well as the variation associated with signal 
measurements into consideration, and generates a dimensionless and simple statistical score for 
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each HTS assay. Before the description of z-factor, there was no generally accepted and 
systematic approach to evaluate the “quality” of a HTS assay. Z-factor scores between 0 to 0.5 
indicate a very good HTS assay, while values between 0.5 to 1.0 illustrate an excellent assay. 
Our liver stage screen demonstrated values of 0.131, 0.409, -0.482 respectively for atovaquone. 
The negative value demonstrated for the last trial run of atovaquone does not indicate that our 
liver stage screening assay is not robust because Z` was originally created and optimized for 
single well, HTS screening assays testing libraries >500,000 compounds and not optimized for 
medium-large scale dose response assays like ours, testing compound libraries in the 2,000 
compound range. It has been reported that the high-sensitivity of the statistical test has lead to 
potentially unfavorable Z-factor scores due to extreme values in either the positive or negative 
control groups, generating misleading changes in z-factor despite the assay performing well in 
the actual screen (110). Therefore, the low score observed on the last trial run for atovaquone is a 
misleading Z-factor score. In addition, the z-factor score for trials one, two and three for 
ICI56,780 were 0.340, 0.353, and 0.684 respectively. The z-factor calculated for all three runs 
for ICI56,780 demonstrated that our HTS assay is an excellent screening system, producing very 
robust, reproducible data. 
We also performed the Kruskal-Wallis one-way ANOVA on the IC50 values for each 
compound. In both cases, the Kruskal-Wallis test demonstrated that the IC50 values within each 
drug trial were not statistically different from one another. We chose to analyze our data using a 
second statistical analysis method, Kruskal Wallis, to highlight the fact that there is no perfect 
statistical analysis program for our drug assay because the results of the analyses are relevant to 
the perspective of the analysis program used. In this case, the Kruskal Wallis also indicated that 
the HTS produces reliable and precise half maximal inhibitory concentrations for the compounds 
 53 
tested. It is however, also very important to highlight that even when we tested our HTS values 
in the extremely stringent statistical analysis method, Z`, our data still resulted in high Z` values, 
indicating that the drug assay we developed is of an excellent quality. 
Furthermore, our liver stage assay was applied for a large chemical library screen to 
determine the IC50 values of many different compounds from not only the Manetsch laboratory 
(Northeastern University, Boston, MA), but also from our collaborators at St. Jude Children’s 
Research Hospital (Memphis, TN) and University of Central Florida (Orlando, Florida). Table 
2.2 illustrates some of the most potent liver stage active compounds we tested, called the 
exemplar compounds for the purposes of this dissertation. The results produced from our liver 
stage screen investigating the SAR of 4(1H)-quinolones in regards to their antimalarial activity 
have been recently published in the Journal of Medicinal Chemistry (108). In summary, the 
4(1H)-quinolone series possess potent erythrocytic and exoerythrocytic activity with many of the 
compounds displaying low nanomolar EC50 values and demonstrated no toxicity in cytotoxic 
assays. Unfortunately, most of the compounds were not efficacious in vivo, which we believe is 
due to poor aqueous solubility and low oral bioavailability. However, the liver stage data in 
conjunction with blood stage testing still resulted in invaluable knowledge gained. We showed 
that the 3-ester group is an extremely important moiety against liver stage parasites and this 
structure may answer some of the questions we have about atovaquone cross-resistance. The 
liver stage data demonstrated that there is considerable potential in this scaffold, which may be 
further optimized for solubility and stability. Medicinal chemistry modifications could lead to 
curative and orally bioavailable antimalarial drugs active against all stages of malaria. Our liver 
stage screen was also involved in assessing the exoerythrocytic activity of a set of soluble 
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piperazine containing 4(1H)-quinolones, which is described in another manuscript, which is in 
the final pre-submission phases.  
 
Conclusion 
Our study demonstrates that we have successfully developed a HTS liver stage assay 
producing reliable and reproducible results that has been used to screen diverse, large chemical 
libraries for the identification of liver stage active compounds. The capability of liver stage HTS 
at USF allows for malaria drug discovery laboratories to send their compounds to us for liver 
stage activity screening. The results obtained from the liver stage drug screen have been featured 
in medicinal chemistry journals describing the development of potential antimalarials that may 
resolve the antimalarial drug crisis that we are currently faced with. A third manuscript, 
describing localization studies in asexual and sexual stage malaria parasites, also utilized our 
liver stage screening assay to demonstrate the activity of novel 8-AQ florescent probes they 
developed. The technology we developed allows chemists and fellow malaria researchers to 
screen more drug compounds even with limited resources and drives the malaria drug discovery 
front forward. Hopefully with the liver stage screen, we will be able to discover an antimalarial 
compound that will end malaria in the next decade. 
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Mosquito age 
upon feeding 
No. infected midgut (%) Midgut infection 
score 
Sporozoites per 
mosquito 
3 
 
34/58 (58.6%) ++++ 15,798 
47/47 (100%) ++++ 11,207 
4 
 
36/60 (60%) ++++ 81,178 
8/10 (80%) ++++ 56,500 
5 
 
24/37 (64.8%) +++ 7,789 
19/38 (50%) ++++ 14,274 
6 
 
50/50 (100%) +++ 5,989 
13/17 (76.4%) ++ 269 
 
 
Table 2.1 Effects of Mosquito Age and Sporozoite Production. Four-day-old mosquitoes were 
to be the optimal age for feeding. Although three-day-old mosquitos produced a decent 
sporozoite infection, interest to take a blood meal decreased significantly with younger 
mosquitoes. Additionally, older mosquitoes (five and six-day-old) produce mid-level infections, 
however their mortality rates increased significantly, reducing the number of live mosquitoes by 
day 21, which is the day for salivary gland harvest. 
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Table 2.2 Exemplar Compounds Resulting From HTS Liver Stage Assay. Various sources 
including St. Jude Children’s Research Hospital, Roman Manetsch laboratory, and University of 
Central Florida Department of Chemistry have sent potential antimalarial compounds to be 
screened for liver stage activity. Featured are some of the exemplary compounds that possess 
low nanomolar activity, which represent ideal antimalarial candidates for further development. 
The compounds highlighted in red represent some of the most active compounds identified in our 
compound library. 
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Figure 2.1. Sporozoite Production. A) Infected rodent malaria blood is injected into naïve 
Balb/C mice via intraperitoneal injection. B) Parasitemia is monitored biweekly via Giemsa 
smear. C) When parasitemia reaches >4% and <8% with gametocytes seen, mice were 
anesthetized with a solution of ketamine and xylazine and placed over a carton of 3-4 day-old, 
starved, female Anopheles mosquitoes. D) On day 10 post-feed, mosquitoes were checked for 
oocysts via midgut dissection. E). On day 21 post-feed, the mosquitoes were aseptically 
dissected for their salivary glands, which contain sporozoites. 
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Figure 2.2. Liver Stage Assay Workflow. A) Hepatocytes were counted in a hemocytometer 
and seeded 24 hours prior to experiment start time at an optimized density of 17,500 cells per 
well in a 384-well rat tail-1 collagen coated plate. B) Mosquitoes were aseptically grown 
approximately 1 month prior to dissection date and infected with parasites. Sporozoites harvested 
were diluted and counted in a hemocytometer and then added at an optimized 4,000 sporozoites 
per well and the plate was then placed into 37°C. C) After a 3 hour incubation at 37°C, media 
was removed and drugs were added to their respective wells. D) A 44-hour incubation period 
yields our end point where we lysed the cells with Promega Cell Lysis Reagent Buffer and add 
Promega Luciferase Assay Reagent. The amount of light emitted, read by the Perkin Elmer 
EnVision system, indicates parasite viability. If the parasite is affected by the drug and thus is 
not longer viable, then the luciferase signal will no longer be emitted, thus determining the 
viability of the sporozoites after drug treatment. A growth curve was generated from this data to 
determine IC50 values and thus efficacy of the compound against liver stage parasites. 
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Figure 2.3. Validation of Liver Stage Assay.  a) Atovaquone was tested at maximum 
concentration of 200 ng/ml with a 1:3 dilution. The IC50 for atovaquone in the liver stage assay 
was found to be 0.28 ng/ml (1.42 nM), which is similar to values reported by previous studies. 
As extra validation ICI56,780 was tested at maximum concentration of 1 ng/ml with a 1:3 
dilution. The IC50 was found to be 0.02 ng/ml (52 pM). b) Both dose response curves were tested 
with z-factor (Z`) statistical analysis, and scores illustrated that our liver stage assay is an 
extremely robust and reproducible HTS assay. 
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b) 
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Figure 2.4: Scatter and Box Plots of Activity Values for St. Jude’s Compounds 
Screened. (a) Scatter plot of activity were normalized and raw activity at 100 indicates 
100% growth inhibition while zero raw activity represented 100% parasite growth. An 
algorithm was used to show the dose response curves of each active compound, which 
are denoted by the blue dots. (b) The box plot of activity values was produced for quality 
control purposes and for illustrating the robustness of the data. All compounds tested fall 
within the black boxes. The slender box highlights the reactive compounds. The positive 
(green) and negative (red) controls are very far apart and thus do not over lap. The 
confidence intervals also do not overlap and z-prime is  > 0.5, showing robust data.  
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Chapter Three 
 
Menoctone Resistance in Plasmodium berghei and Plasmodium falciparum 
 
Note to Reader 
This chapter has been submitted to Antimicrobial Agents and Chemotherapy prior 
to dissertation defense.  
 
Abstract 
Malaria related mortality has slowly decreased over the past decade through the 
efforts of programs such as the World Health Organization and the Bill and Melinda 
Gates Foundation; however, eradication of malaria requires the development of 
antimalarial chemotherapies to remain ahead of resistant parasite strains. Often new leads 
can emerge from older compounds that were once abandoned for a variety of reasons. In 
this study we report on the characterization of menoctone potency against blood and liver 
stages of malaria in vitro and in vivo. Luciferase expressing P. berghei infections in 
HepG2 found menoctone to be extremely potent (IC50 = 0.41 nM). In fact, in these 
assays, menoctone proved to be approximately three fold more potent than atovaquone.  
Previously, Peters and colleagues generated a menoctone resistant line of P. berghei (Pb 
MEN). We first assessed the potential for cross-resistance between menoctone and 
atovaquone in the Pb MEN line and found incomplete resistance. Pulse exposures of 
atovaquone to mice infected with Pb MEN resulted in rapid selection of atovaquone 
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resistance. The results demonstrate sporozoite transmission of resistant parasites; the 
results also offer insight into potential mechanism(s) of resistance to menoctone. 
 
Introduction 
Despite the decline in deaths caused by malaria in the last 10 years, the disease 
threats from infections with Plasmodium spp. still pose a significant global public health 
problem. In 2015 alone, the World Health Organization estimates that malaria caused 214 
million clinical cases and 438,000 deaths (1). The increased prevalence of drug resistant 
parasites and insecticide-resistant vectors continues to drive the need for new treatments 
for this disease.  New drugs are urgently needed and in some cases old compounds with 
proven antimalarial activity can serve as the basis for lead optimization of new potent 
antimalarial drugs (111). Menoctone, also known as 2-hydroxy-3-(8-cyclohexyloctyl)-1,-
4-naphthoquinone, was first synthesized by Fieser et al in 1948 (112). Initial studies with 
menoctone and analogs thereof reduced parasitemia, but failed to prevent recrudescence 
at safe, non-toxic levels of drug administration in blood stages (112). In 1965, Howland 
used rat liver mitochondrial preparations to model how menoctone and various 
naphthoquinones inhibited the respiratory chain between cytochromes b and c1 (113). 
Intriguingly, Skelton et al showed that menoctone, when tested in vitro at concentrations 
of 10 - 25 nM inhibited the nicotinamide adenine dinucleotide (NADH) peroxidase of P. 
berghei by 90% (114). Specific morphological changes such as swelling and thickening 
of the mitochondria as well as reduplication of mitochondrial membranes were observed 
in intraerythrocytic trophozoites of P. berghei infected mice exposed to menoctone (115, 
116). Peters et al later reported the ED50 and ED90 values against the N-strain of P. 
 64 
berghei, as 0.7 and 1.5 mg/kg, respectively, and showed an effective causal prophylactic 
dose of 1-3 mg/kg against P. yoelii nigeriensis (113). Later studies with menoctone 
treatment of the pre-erythrocytic stages in rodent malaria models demonstrated efficacy 
2.5 times greater than primaquine (117). All of the previous studies lead to menoctone 
progressing to clinical trials, but disappointingly it proved less effective against P. 
falciparum as compared to other antimalarials under development at the time. Thereafter, 
research on menoctone was discontinued due to the low curative activity and the potential 
for development of resistance reported in P. berghei. When administered daily at doses 
ranging from 6.25 to 25 mg/kg for five consecutive days, the cure rate for menoctone was 
low, where only four of 72 mice remained parasite-free for 28 days (117). Since resistant 
parasites were readily selected for, Peters et al created a highly resistant line of P. berghei 
against menoctone through serial technique (113). The menoctone resistant line was not 
responsive to challenge by primaquine and cycloguanil; however, remained sensitive to 
mefloquine, chloroquine, pyrimethamine and sulfadoxine. When tested for transmission 
blocking activity, menoctone showed no sporontocidal activity as demonstrated by 
successful oocyst and sporozoite development (118). Although menoctone is not 
currently used for malaria prevention or treatment, it is an effective treatment at low 
intravenous and intramuscular doses against Theileria parva, a parasitic protozoan that 
causes East Coast Fever in cattle (119). Intramuscular doses were preferred over 
intravenous administration and oral administration proved to be ineffective (120). The 
efficacy of menoctone against T. parva is quite remarkable, but the complexity of 
compound synthesis and high manufacturing costs rendered menoctone unmarketable as 
theileiosis treatment (121).  
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Previous studies with menoctone did not reveal a mechanism of action, although 
the chemical structure of menoctone reveals a similar core scaffold to atovaquone (Figure 
1). Atovaquone-proguanil (AP) is a fixed-dose combination antimalarial that is currently 
used for prophylaxis as well as treatment of Plasmodium falciparum. Atovaquone affects 
the malaria parasite by binding to the quinol oxidation (Qo) site of cytochrome b (cyt b) in 
the mitochondrial respiratory chain. Atovaquone-resistant isolates have been described 
following atovaquone or AP treatment (122-126).  In vitro studies of atovaquone with P. 
falciparum have selected for point mutations at multiple sites in P. falciparum 
cytochrome b (pfcytb); however, the predominant clinical resistance mutation seen in 
patient isolates is Y268S. In contrast, in vivo studies with P. berghei have selected for 
mutations in pfcytb, specifically M133I, a mutation commonly seen with P. falciparum in 
vitro resistance selections (127, 128).  
Since menoctone is structurally similar to atovaquone and displays activity 
against liver stages of P. berghei (117), we hypothesize that menoctone shares a similar 
target as atovaquone and may generate similar mutations in pfcytb that confer cross-
resistance to atovaquone. In this study, we generated menoctone resistant parasites in 
both P. berghei and P. falciparum and sequenced cytb to better understand the 
mechanism(s) of resistance to menoctone and potential for this compound to serve as a 
lead for antimalarial drug development.  
 
Materials and Methods 
Parasites and Animals.  We used P. falciparum W2 that was cloned from an 
Indochina isolate by Oduola et al in 1988 (129). Human O+ red blood cells and plasma 
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for culturing P. falciparum were obtained from Interstate Blood Bank (Memphis, TN). 
All in vitro cultured parasites were maintained according to previously published 
methods (130).  
Menoctone resistant P. berghei MEN (MRA-414) was obtained from Malaria 
Research and Reference Reagent Resource Center (MR4); the line was originally 
generated by Professor Wallace Peters (131, 132). P. berghei 1052 Cl1 (Pb 1052 Cl1) 
was obtained from C.J. Janse at Leiden University and was used for menoctone resistance 
selections. This line was generated from the reference ANKA clone c1115cyl and 
expresses both green fluorescent protein (GFP) and firefly luciferase (100). Pb 1052 Cl1 
has two copies of the GFP-luc incorporated into its genome. One copy is regulated by a 
constitutively expressed eef1aα promoter, and the other is an ama1 promoter (100, 101).  
All mice used in these experiments were female Balb/C mice (average weight was 
approximately 20g) obtained from Harlan/EnVigo (Indianapolis, IN) and from Charles 
River (Wilmington, MA). Rodent malaria parasites were monitored via modified Giemsa 
stained blood from tail vein smears, and parasitemia was determined via light 
microscopy. Parasites were passaged by removing blood via cardiac venipuncture and 
inoculating the intraperitoneal cavity of a new mouse with parasite infected blood. Mice 
were humanely euthanized when parasitemia reached 40% or the animal showed sequelae 
of malaria. This study was conducted in compliance with the Guide for the Care and Use 
of Laboratory Animals of the National Research Council for the National Academies and 
the University of South Florida Institutional Animal Care and Use Committee approved 
the animal use protocols. 
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Drugs and Chemicals. Atovaquone was obtained from Sigma Aldrich (St. Louis, 
MO). Menoctone was not commercially available at reasonable costs and the published 
synthesis methods required improvement, therefore a new method was devised and is 
described herein.  
 
Susceptibility Assessment of P. berghei Liver Stages In Vitro.  
Mosquito Infections and Sporozoite Isolation. Mice were infected using 
previously described methods above. When parasites reached >4% parasitemia, mice 
were anesthetized using ketamine (100 mg/kg) and xylazene (10 mg/kg) and placed on 
cartons containing 100 naïve female, 3-4 day old Anopheles stephensi (mosquitoes 
obtained from Kim Williamson at Loyola University). Mosquitoes fed for 25 minutes and 
were maintained on 10% sucrose ad libitum inside environmental chambers at 22°C. On 
day 10 post-exposure (PE), 50 mosquitoes were checked for midgut infection through the 
visualization of oocysts on the midgut. On day 21 PE, infected salivary glands were 
dissected and sporozoites were isolated and counted. 
Liver Stage Drug Susceptibility Assay. HepG2 cells (17,500 cells/well) 
were seeded in black 384-well collagen coated plates with optically clear bottoms 
(Becton Dickson, Franklin Lakes, NJ). Cells were seeded using the Tecan Freedom Evo 
robotic system (Tecan Group Ltd, Männedorf, Switzerland) at 50 µl per well and were 
maintained at 37°C in 5% mixed gas humidified incubators. Complete media consisted of 
Eagle’s Minimum Essential Medium, supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, and 1% L-glutamine. Mosquito dissections were harvested as 
described above, and 4,000 sporozoites were added to each well. Plates were incubated at 
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37°C for three hours and then media was removed and serially diluted drugs that were 
previously prepared were added to the respective wells (65). After 44-hour incubation 
period we lysed the cells with 5 µl of Promega Cell Lysis Reagent Buffer and added 20 µl 
Promega Luciferase Assay Reagent (Promega, Madison, WI). Luciferase activity in 
parasite lysates was quantified by using the Perkin Elmer EnVision (Perkin Elmer, 
Waltham, MA). An IC50 dose response curve was generated from this data in GraphPad 
Prism (GraphPad Software, Inc., La Jolla, CA) to determine the efficacy of drugs against 
liver stage parasites.  
P. falciparum Asexual Blood Stage Susceptibility.  Parasitemia was cultured 
and allowed to grow to approximately 5% parasitemia where it was then synchronized at 
ring stages by using a sorbitol method as previously described (133). Drug dilutions were 
prepared in 96-well plates and were tested in duplicate using a 1:3 dilution series with a 
starting concentration of 10 µg/mL for menoctone and 62.5 ng/mL for atovaquone. Drugs 
were allowed to act on parasite development for 48 hours. [3H]hypoxanthine was diluted 
1:20 and added at 10 µl per well to the whole plate. Radioactive plates were placed into a 
specially contained incubator reserved only for hypoxanthine treated plates for another 24 
hours. Plates were then removed and placed in an -80°C freezer for an additional 24 
hours. Cells were harvested using the Perkin Elmer MicroBeta FilterMate-96 Harvester 
(Perkin Elmer, Waltham, MA). We used the TopCount Luminometer (Perkin Elmer, 
Waltham, MA) to read and determine the fifty percent inhibition concentration (IC50) of 
drugs added to the asexual parasites (98).  
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Selection of Menoctone Resistance in P. falciparum In Vitro and Mutation 
Detection. 
W2 Menoctone Resistance Selection. Parasite line W2 was grown to 
10% parasitemia, then 108 parasites were seeded in fresh parasite culture media 
containing ~10x IC50 concentrations (1.5 µM) menoctone. Media was changed with fresh 
menoctone and blood smears were made twice per week, with fresh erythrocytes added as 
needed. Cultures were split 1:3 every 10 days, and cultured until parasite recovery was 
observed (2% parasitemia) in presence of menoctone.   
Genomic DNA Extraction (W2). Parasite genomic DNA extraction was 
performed with an initial lysis step in 1x PBS+0.01% saponin, followed by extraction 
using the Qiagen MiniBlood Prep Kit according to manufacturer’s instructions.  Genomic 
DNA (gDNA) was assessed for concentration and purity on a NanoDrop 
spectrophotometer.   
PCR Amplification and Sequencing of Pf-cytochrome b. PCR primers 
were designed for amplification based on the annotated P. falciparum 3D7 cytochrome b 
sequence (MAL_MITO_3) on Plasmodb.org v27 as follows: Pf-cytb-PCRFOR: 5’—
TGCCTAGACGTATTCCTG—3’ and Pf-cytb-PCRREV 5’—
GAAGCATCCATCTACAGC—3’. PCRs were amplified using Phusion HS II High-
Fidelity PCR Master Mix (ThermoFisher Scientific, Grand Island, NY) with ~20 ng 
parasite gDNA template, according to manufacturer’s instructions with the following 
program: 98°C—30s initial denaturation step, then 35 cycles: (98°C—10s, 54°C—40s, 
72°C—30s) and a final extension of 72°C for 7 min.  PCR products were confirmed as a 
single, discrete band of 1,382 bp length on a 1% agarose gel then subsequently purified 
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using the Qiagen PCR Purification Kit according to manufacturer’s instructions. Purified 
PCR products were prepared for Sanger sequencing service at Genewiz (Genewiz, South 
Plainfield, NJ) using the following sequencing primers: pf-cytb-SEQFOR1: 5’—
GTGGAGGATATACTGTGAGTG—3’, pf-cytb-SEQFOR2: 5’—
TACAGCTCCCAAGCAAAC—3’, pf-cytb-SEQREV1: 5’—
GACATAACCAACGAAAGCAG—3’, and pf-cytb-SEQREV2: 5’—
GTTCCGCTCAATACTCAG—3’. PCR primers Pf-cytb-PCRFOR and Pf-cytb-
PCRREV were also used for sequencing purposes.  
Analysis of Pf-cytochrome b Sequences for Mutation Detection. 
Sequence files were aligned to P. falciparum 3D7 cytochrome b sequence 
(MAL_MITO_3) using open source software:  A Plasmid Editor (ApE v2.0.49).  Trace 
files were checked at all mutant positions to validate any mutations found.   
  
Generation of Menoctone Resistance in P. berghei and Mutation Detection. 
We used similar methods as used by W. Peters to generate a new menoctone resistant 
parasite from the well-characterized P. berghei luc ANKA (113). Infected mice were 
treated with increasing levels of menoctone at doses of 3 mg/kg, 30 mg/kg, and 300 
mg/kg. Recrudescent parasites were inoculated into new mice, and subsequent treatment 
with higher doses of drug led to resistance at a dose of 300 mg/kg. Resistance was 
confirmed by the lack of response to subsequent inoculation of high doses of menoctone. 
A maintenance dose of 300 mg/kg was used to maintain a high level of parasite 
resistance.  
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Genomic DNA extraction (Pb MEN-R). Parasite genotyping was 
performed by sequencing cardiac venipuncture blood containing parasites at high 
parasitemias (>40%) that were majority schizonts. Murine leukocytes were removed by 
treating the blood with Ficoll-Paque PLUS (GE Healthcare Life Sciences, Waltham, 
MA). Parasite genomic DNA extraction was then performed as described earlier. 
PCR Amplification and Sequencing of Pb-cytochrome b. PCR primers 
were designed for amplification based on the annotated P. berghei cytochrome b 
sequence (PBANKA_MITO1900) on Plasmodb.org v27 as follows: Pb-cytb-PCRFOR: 
5’—TGCCTAGACGTATTCCTG—3’ and Pb-cytb-PCRREV 5’—
GCTGAGCATGTTAACTCG—3’. PCRs were amplified similarly with the following 
program: 98°C—30s initial denaturation step, 35 cycles: (98°C—5s, 54°C—10s, 72°C—
39s) and a final extension of 72°C for 7 min.  PCR products were confirmed as a single, 
discrete band of 1,307 bp length on a 1% agarose gel then subsequently purified and 
sequenced as described earlier, using the following primers: pb-cytb-SEQFOR1: 5’—
GTGGAGGATACACTGTTAGTG—3’, pb-cytb-SEQREV1: 5’—
CATAACCTATAAAAGC—3’, pb-cytb-SEQREV2: 5’—
GTTTGCTTGGGAGCTGTA—3’. PCR primers Pb-cytb-PCRFOR and Pb-cytb-
PCRREV were also used for sequencing purposes.  
Analysis of Pb-cytochrome b Sequences for Mutation Detection. 
Sequence files were aligned to P. berghei cytochrome b sequence 
(PBANKA_MITO1900) as described previously. 
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In Vivo Antimalarial Efficacy Against Blood Stages of P. berghei Life Cycle 
(Modified Thompson Test). Concisely, five mice were randomly assigned to each 
dosage group. P. berghei luc ANKA, as well as, Pb MEN-R were inoculated at 2x106 
parasites per mouse. Menoctone was administered orally at 3 mg/kg, 30 mg/kg and 300 
mg/kg and atovaquone was administered at 1 mg/kg, 3 mg/kg and 10 mg/kg. Both drugs 
were suspended in polyethylene glycol 400 (PEG 400) (Sigma Aldrich, St. Louis, MO) 
and administered via oral gavage at 100 µl per mouse. Dosing by oral gavage occurred 
once daily for 3 days on days 6 to 8. Blood films were made on days 3, 5, 6, 9, 12, 15, 18, 
21, 24, 27, and 30 post-infection from tail vein blood to monitor parasite recrudescence.  
Elucidation of Mutation Selection by Atovaquone or Menoctone. Sensitive 
and resistant parasites were inoculated into mice and challenged with either atovaquone 
or menoctone at different concentrations. Atovaquone was administered to mice at 
dosages of 1 mg/kg, 3 mg/kg, and 10 mg/kg, and menoctone was given at 3 mg/kg, 30 
mg/kg, and 300 mg/kg respectively. Parasitized blood was then removed and sequenced 
for cytb mutations. 
P. berghei MEN (MRA-414) Assessment of Atovaquone Cross-Resistance. 
Mice were infected with P. berghei MEN and allowed to grow to >4% parasitemia at 
which point were challenged with atovaquone at 3 mg/kg, 30 mg/kg and 100 mg/kg. 
Subsequent administration of atovaquone at 100 mg/kg was used as confirmation of 
atovaquone resistance.  
Transmission of Menoctone Resistant P. Berghei to Mosquitoes. Resistant 
parasites were passaged and maintained using methods described above. Once the 
parasitemia reached 3-5%, the mice were anesthetized with a solution of xylazene (10 
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mg/kg), ketamine (100 mg/kg), then placed on cartons of 200, 3-4 day old, naïve female 
Anopheles stephensi mosquitoes. Mosquitoes were allowed to feed for approximately 25 
minutes and maintained on 10% sucrose inside environmental chambers at 22°C. On day 
10 PE, 50 mosquitos were checked for midgut infection through the visualization of 
oocysts on the midgut wall. Oocysts were scored based on two different characteristics: 
the percentage of midguts infected with oocysts and the quality of infection. The 
percentage of midguts infected was calculated by dividing the number of infected 
midguts by the total number of midguts dissected, then multiplying the result by 100. 
Each midgut was also graded by the following scale to determine the quality of infection: 
0-50 oocysts received a +; 51-100 oocysts received a ++; 101-150 oocysts received a 
+++, 151-200 oocysts received a ++++; and greater than 200 oocysts in a midgut 
received +++++. On day 21 PE, the mosquitoes were dissected for salivary glands in 
order to visualize the presence sporozoites.  
P. berghei luc Menoctone Resistant Sporozoite Liver and Blood Stage 
Infection. On day 21 PE, we harvested sporozoites and infected five female mice with 
10,000 sporozoites per mouse via tail vein injection. Once parasites were visualized in 
peripheral blood smears, two of the five mice were treated with 300 mg/kg of menoctone 
to confirm parasite resistance, while the remaining three were kept as controls. Cardiac 
venipuncture was used to collect blood from all five mice and leukocytes were removed 
prior to parasite genotyping. 
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Results 
Synthesis of Menoctone. Although first identified as an antimalarial by Fieser 
and co-workers in collaboration with Sterling-Winthrop Research Institute in 1948 (134), 
it wasn’t until 1969 that Lorenz patented a synthetic route for menoctone starting from 5-
phenylvaleric acid (135). Dolan et al reported that this synthesis had many shortcomings 
requiring costly raw materials, harsh reaction conditions, and some low yielding synthetic 
steps (119). In an effort to design a facile synthetic route for menoctone, we developed a 
novel convergent approach involving modern and classical transformations (Figure 1). 
Isochroman-1,4-dione 1 was synthesized from 2-acetylbenzoic acid, which was first 
brominated and then cyclized. The copper mediated alkane synthesis of 1-bromo-7-
chloroheptane and allylmagnesium bromide afforded chloroalkene 2 (136). Substitution 
of the chloride with iodide via a Finkelstein reaction afforded iodoalkene 3 which was 
then treated with cyclohexylmagnesium bromide in another copper mediated alkane 
synthesis to afford the allylcyclohexane 4. Lemieux-Johnson oxidation of allyl 4 yielded 
aldehyde 5.  Condensation of aldehyde 5 with isochroman-1,4-dione 1 afforded 3-
substituted isochroman-1,4-dione 6, which was rearranged to menoctone using sodium 
methoxide in methanol (Figure 3.1). This new synthetic route was facile, required fewer 
steps, produced better yields, and utilized less expensive reagents than the previously 
published method. 
Efficacy of Menoctone Against Exoerythrocytic and Blood Stage Parasites.  
Previous studies demonstrated menoctone is efficacious against asexual blood stage as 
well as liver stage parasites, yet these studies were done in vivo before the advent of 
quantitative in vitro susceptibility assays. Therefore we first profiled the activity of 
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menoctone against asexual blood stages of P. falciparum in vitro. The IC50 was 113 nM 
against W2, a clone that is resistant to chloroquine, pyrimethamine, and sulfadoxine. 
Next we assessed the activity of menoctone against P. berghei liver stages infecting 
HepG2 hepatoma cells in vitro. In these assays menoctone proved to be extremely 
efficacious (IC50 = 0.41 nM) and was approximately three fold more potent than 
atovaquone (Figure 3.2). 
Menoctone Resistance Selection in P. falciparum. Based upon structural 
similarity between menoctone and known mitochondrial electron chain inhibitors, we 
hypothesized that cytochrome bc1 is the site of action of menoctone. A common way to 
identify mechanisms of action is the selection of resistance to an inhibitor followed by 
sequence of the putative target or whole genome. We used standard methods to select for 
resistance to menoctone in P. falciparum (W2). We grew 108 asexual erythrocytic stage 
parasites and exposed them to constant drug pressure of 1.5 µM menoctone. Initial 
exposure of W2 to menoctone resulted in pyknotic forms and parasites outside of 
erythrocytes after 48 hours, followed by a gradual reduction of parasites observed in thin 
smears. However, on day 23 of menoctone exposure, parasites recovered to healthy 
morphology and reached 2% parasitemia, which were expanded further under menoctone 
pressure. We sequenced the parasites to identify mutations in cytochrome b and found the 
menoctone resistant progeny had a non-synonymous SNP (G to C at nucleotide 399) that 
resulted in a M133I mutation (Table 3.1).  
Menoctone Resistance Selection in P. berghei. In previous studies Wallace 
Peters and colleagues found that resistance to menoctone was selected rapidly in P. 
berghei in vivo (113); however, these parasites have not been fully characterized or 
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genotyped. Therefore, we aimed to select for resistance in P. berghei luc ANKA by using 
a stepwise selection method. First we infected mice with asexual erythrocytic stages and 
treated with a single dose (3 mg/kg) of menoctone and no decrease in parasitemia was 
observed post treatment (Figure 3.3 A).  Blood from these mice was then inoculated into 
two malaria naïve mice and once patent infections ensued, we treated with a single dose 
of menoctone (30 mg/kg) (Figure 3.3 B). In these mice parasitemia decreased to <1% 
three days post treatment, but recrudesced to approximately 30% six days later. Once 
again blood from the recrudescent infections (day 6) were inoculated into malaria naïve 
mice and the treatment dose was escalated to 300 mg/kg (Figure 3.3 C). As noted in 
Figure 3C, parasitemia reduced rapidly after treatment, yet recrudesced a few days later. 
Parasitemia in these mice was low so we immediately sub-inoculated the infected blood 
into more malaria naïve mice and repeated the single high dose of menoctone (300 
mg/kg). In these mice parasitemia continued to increase at a rapid rate despite treatment, 
thus indicating selection of highly resistant parasites to menoctone (Figure 3.3 D). The 
menoctone resistant P. berghei luc ANKA parasite is hereafter referred to as Pb MEN-R 
(Figure 3.3). 
Confirmation of Menoctone Resistance in Pb MEN-R Infected Mice.  Next we 
aimed to assess the efficacy of menoctone and atovaquone in the standard Thompson 
efficacy assay. In these studies, mice were inoculated with parasites and after parasitemia 
reached ~1% mice were treated once a day for three days with drug. Efficacy was 
assessed by reduction of parasitemia on day 9 (one-day post drug treatment) as well as 
cure rate (survival to day 30 of the study). The doses used were 1, 3, and 10 mg/kg for 
atovaquone and 3, 30, and 300 mg/kg for menoctone. In these studies, we confirmed that 
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atovaquone was more efficacious than menoctone against asexual blood stages of P. 
berghei luc ANKA as well as Pb MEN-R (Figure 3.4 C, A and D, B). Interestingly there 
was evidence of atovaquone cross-resistance in Pb MEN-R as evidenced by lower 
survival rates in Pb MEN-R versus Pb ANKA following treatment with atovaquone 
(Figure 3.4 C, D). These studies confirmed that Pb MEN-R is highly resistant to 
menoctone when compared to the response of the parental line P. berghei luc ANKA 
(Figure 3.4 B, A).  
Menoctone Resistance Genotype in P. berghei. Next we compared the 
cytochrome b genotype of the parent P. berghei luc ANKA line and the menoctone 
resistant Pb MEN-R progeny. Sanger sequencing revealed the same M133I mutation in 
Pb MEN-R that we observed in menoctone resistant P. falciparum (W2 MEN-R) (Table 
S1). The SNP identified (G to T, nt 399) is located outside of the quinol oxidation site 
(Table S1) and is the same SNP as observed in previous studies in which atovaquone was 
used to select for resistance (127). Although we did not have access to the parental line, 
we obtained the P. berghei MEN (MRA-414) line selected for resistance to menoctone by 
W. Peters (113) and sequenced cytochrome b. Interestingly in Pb MEN (MRA-414) we 
observed a G to T mutation at nucleotide position 397 that confers a M133L mutation 
(Table 3.1). These data suggest that menoctone resistance is conferred by similar 
mutations in cytochrome b in both P. berghei and P. falciparum and that these mutations 
confer cross-resistance with atovaquone.  
 A previous study suggested rapid selection of menoctone resistance in P. berghei, 
therefore we next aimed to evaluate if M133I is readily selected in a single passage. In 
this study we challenged both sensitive and resistant menoctone parasites to single dose 
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exposures of different doses of menoctone or atovaquone. After one round of atovaquone 
or menoctone treatment, we found WT cytb in all of the menoctone sensitive parasites. 
All of the Pb MEN-R parasites, regardless of the treatment demonstrated the M133I 
mutation (Table 3.1).  
Assessment of Atovaquone Cross-Resistance on P. berghei MEN Resistant 
Parasites. Upon initial treatment with 3 mg/kg of atovaquone, parasitemia decreased to 
<1% in Pb MEN infected mice; however, parasites never completely cleared. Parasites 
recrudesced by day six post-treatment and 10% parasitemia was reestablished by day nine 
(Figure 3.5 A). Blood was passaged into naïve Balb/C mice and a higher dose of 30 
mg/kg atovaquone decreased the parasitemia to <1% (Figure 3.5 B). Resistant parasite 
populations recrudesced faster, four days post-treatment when compared to the first drug 
exposure, 9 days. Again, a higher dose of atovaquone (100 mg/kg) brought the 
parasitemia down to <1%, and parasites recrudesced by day seven post-treatment (Figure 
3.5 C). Successive treatment with a high dose of atovaquone (100 mg/kg) failed to clear 
parasites from peripheral blood (Figure 3.5 D). 
Mosquito Transmission of Menoctone Resistance. Recent studies have 
suggested resistance to atovaquone that is mediated by cytochrome b mutations is not 
transmissible through mosquitos (137). We aimed to test that hypothesis with the Pb 
MEN-R parasites generated in this study. First we inoculated mice ip with Pb MEN-R- or 
Pb ANKA-infected erythrocytes, collected blood for cytochrome b genotyping, and then 
fed adult female A. stephensi mosquitos on the infected animals. On day 10, midgut 
dissections revealed 32.6% of mosquito midguts were infected with oocysts of Pb MEN-
R (Table 3.2). Mercurochrome staining of midguts showed healthy, round oocysts with 
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definitive borders. Each midgut contained approximately 130 oocysts and produced a 
qualitative score of +++. On day 21 (D21), salivary glands were dissected and yielded 
approximately 200,000 sporozoites of Pb MEN-R. In contrast, infections with Pb luc 
ANKA produced higher rates of oocyst development and sporozoites per mosquito, as 
compared to Pb MEN-R.  Some sporozoites were used to extract gDNA and the rest were 
used to inoculate iv into five malaria naïve Balb/C mice. Three of the mice infected with 
Pb MEN-R were not treated with drug and produced patent blood stage infections 12 
days PI. The two Pb MEN-R infected mice that were treated with menoctone (300 
mg/kg) demonstrated menoctone resistance as evidenced by continued growth despite 
treatment with the highest dose of drug.  
As noted above, at each stage of the study we collected gDNA and then 
sequenced parasites to elucidate the cytochrome b genotype (Table 3.2). Genotype 
analysis confirmed that Pb MEN-R parasites used for mosquito infections had the M133I 
mutation as did sporozoites dissected from the salivary glands of the mosquitos D21 post 
feed. Furthermore, the M133I mutation was maintained in subsequent sporozoite 
challenge and menoctone resistant erythrocytic stages of Pb MEN-R maintained the 
resistance phenotype and M133I genotype. In simultaneous studies with the parental line 
Pb luc ANKA, we found the WT cytochrome b sequence throughout the transmission 
study. These studies demonstrate that menoctone and atovaquone resistance associated 
with M133I mutations in cytochrome b are transmissible through mosquitos. The only 
differences observed were somewhat lower oocysts and sporozoite yields with Pb MEN-
R as compared to Pb luc ANKA (Table 3.2). Mosquito transmission studies with 
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menoctone resistant P. falciparum were not possible since neither W2 nor W2 MEN-R 
produce viable gametocytes for mosquito infections. 
 
Discussion 
In previous studies we have shown that old, potent drug scaffolds can be 
optimized into clinical candidates (111). Menoctone represents an interesting case where 
there was evidence of efficacy against multiple stages, although much was not known 
since the drug was abandoned shortly after its discovery. Early studies were limited 
mostly to in vivo evaluation in rodent models and a few biochemical analyses. In addition 
the limited reports date back almost 70 years, laying down initial groundwork for 
determining efficacy, yet the mechanism of action of menoctone against malaria is still 
not fully understood. Therefore the major aim of this study was to better profile the 
parasitological efficacy of menoctone and to generate resistance to better understand the 
mode of action. Limited availability of the compound prompted us to develop a new 
synthesis of menoctone using contemporary synthetic approaches. In comparison to the 
original menoctone synthesis (134, 135) our new synthetic route is convergent and 
requires fewer synthetic steps. At the synthetic scale we prepared menoctone, the overall 
yield of our synthetic approach also surpassed the overall yield of the original synthesis. 
Availability of menoctone then enabled us to generate encouraging efficacy data, 
especially the fact that menoctone is much more active against liver stages of P. berghei 
than the approved drug atovaquone. We also were successful at generating menoctone 
resistant malaria parasites that has allowed us to evaluate the possible mechanism(s) of 
action exhibited by menoctone on Plasmodium species. 
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In this study we demonstrated the high potency of menoctone against liver and 
blood stage parasites. We tested menoctone in a quantitative dose response assay for P. 
berghei liver stages and found that menoctone was approximately three fold more potent 
than atovaquone. Further investigation with human blood stage parasites demonstrated 
nanomolar activity against P. falciparum (W2). These results for a putative cytochrome b 
inhibitor are different than most other scaffolds we have studied. Usually potency against 
blood and liver stages are more similar in fold differences when compared to atovaquone. 
In contrast, menoctone is much more potent against liver stages than blood stages. 
Further studies to better understand the pM potency of menoctone for liver stages is 
warranted.  
In the course of generating the menoctone resistant parasite line Pb MEN-R, we 
demonstrated that WT P. berghei under menoctone pressure generates a mutation at 
M133I, which is identical to previous reports of P. berghei under atovaquone pressure 
(127). Since the mutation is located directly outside of the Qo site, the known binding site 
for atovaquone, we believe that menoctone shares the same mechanism of action as 
atovaquone and that is collapsing the mitochondrial membrane potential and disrupting 
pyrimidine biosynthesis, leading to parasite death (138). The stability of resistance in Pb 
MEN-R following passage in untreated mice has not been verified beyond three passages, 
but resistance remains stable following cryopreservation, which is similar to observations 
by on Pb MEN after cryopreservation (113). Pb MEN demonstrated cross-resistance with 
atovaquone and when sequenced, selected for a point mutation allowing for parasite 
survival. Interestingly, Pb MEN selected for the same guanine to tyrosine nucleotide 
change as seen for Pb MEN-R, however, the mutation was located at nucleotide position 
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397. This confers an amino acid change from methionine to leucine. Although Pb MEN 
and Pb MEN-R differ in nucleotide mutations, it is interesting that the nucleotide for 
which the parasite selects for are isomers of one another. The data suggest the M133I or 
M133L mutations inhibit the activity of menoctone or atovaquone to the binding site. Our 
results show, for the first time, the menoctone resistance genotype and suggest a potential 
mechanism of action of menoctone.  
Furthermore, we used a modified Thompson model to demonstrate the in vivo 
activity of menoctone against sensitive and resistant erythrocytic stages of rodent malaria 
(139). A summary of the in vivo results is presented in supplementary table 1. In the 
menoctone drug administered groups, all mice inoculated with sensitive parasites 
exhibited low survival outcomes, and menoctone administration did not provide 
protection for mice inoculated with Pb MEN-R. Alternatively, atovaquone at 10 mg/kg, 3 
mg/kg and 1 mg/kg offered almost complete protection against sensitive P. berghei 
throughout the 30 day study. It is interesting to note that even though 12 out of the 15 
mice survived Pb luc ANKA infection after atovaquone administration, some of the 
surviving mice did present with low levels of parasitemia on day 30 of the study. Overall, 
atovaquone imparted better protection against both Pb luc ANKA as well as Pb MEN-R 
when compared to menoctone, and only high dosages of menoctone, 30 mg/kg and 300 
mg/kg respectively, offer low levels of protection against sensitive P. berghei infection 
(Figure 3.4). This data bolsters the initial findings by Fieser et al that menoctone fails to 
prevent recrudescence of blood stage parasites (112). In addition, our study confirms that 
menoctone resistance confers cross-resistance to atovaquone, which is characterized by 
the healthy and uninterrupted growth of Pb MEN-R in the presence of atovaquone in 
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vivo. When comparing menoctone and atovaquone administration against resistant Pb 
MEN-R, there was a slight delay in parasite recrudescence for atovaquone treated mice, 
indicating perhaps that atovaquone clears more parasites than menoctone, thus requiring 
more time for the parasites remaining in peripheral circulation to recrudesce. This finding 
was expected since the parasites were resistant to menoctone at high levels. Our results 
demonstrate that cross-resistance is clearly present between the two drugs and the 
mechanism by which atovaquone and menoctone act on the parasite are very similar if 
not affecting the same target.  
Previously Coleman et al demonstrated menoctone failure to block transmission 
and successfully produced both oocysts and sporozoites in P. berghei and P. falciparum 
at a dose of 100 mg base drug/kg mouse body weight (118). More recently a study has 
shown that atovaquone resistance can’t be transmitted via mosquitoes (137). This study 
reported that atovaquone drug pressure selects for the M133I cytb mutation in P. berghei, 
which is consistent with our data on menoctone drug pressure. Furthermore they found 
that the P. berghei with M133I or other cytb mutations could not be transmitted through 
mosquitoes. In contrast, we found that P. berghei MEN-R was easily transmitted through 
mosquitoes. We confirmed that the M133I mutation existed in the pre-feed Pb MEN-R 
infected blood that after feeding to An. stephensi produced healthy oocysts and infective 
sporozoites in the mosquito. Genotyping of the resulting sporozoites uncovered the same 
M133I point mutation, which we then compared to its sensitive parent parasites, 
displaying WT cytb. These sporozoites carrying the M133I mutation then successfully 
produced blood stage infection in the next generation of mice. We confirmed that the 
mutation is fully transmittable from sporozoites to mice since all sporozoite-infected 
 84 
mice produced blood stage infection and carried the M133I mutation. To further 
demonstrate that the resistance phenotype was maintained, we administered high doses of 
menoctone to two of the sporozoite inoculated mice to observe parasite growth; despite 
treatment with high dose of menoctone (300 mg/kg) parasitemia continued to rise and 
healthy parasites propagated despite treatment with menoctone. Parasites from these mice 
also maintained the M133I mutation. We conclude that menoctone and atovaquone 
resistant parasites containing the M133I mutation in cytb are indeed transmittable by the 
mosquito vector. At present we do not understand why P. berghei with M133I mutations 
were transmitted in our study, but not in the recent study by Goodman et al (137). The 
difference could be due to inherent transmissibility of the different P. berghei strains or 
mosquitoes used in the respective studies. Another possibility is that yet-to-be identified 
mutations in the nuclear genome may contribute to resistance and transmission potential. 
The transmission potential of parasites resistant to mitochondrial electron chain inhibitors 
warrants additional studies.  
In summary, menoctone proves to be a potent liver stage antimalarial with 
erythrocytic stage efficacy. The compound readily selects for cytb M133I mutation, 
similar to the mutation selected for under atovaquone drug pressure. This leads us to 
hypothesize that menoctone most likely targets the mitochondrial respiration chain of 
Plasmodium. The diminishing arsenal of anti-liver stage compounds sparked our interest 
in reviving the old and previously abandoned compound menoctone. In these studies, we 
have demonstrated for the first time that cytb mutations are transmittable from mouse to 
mosquito to mouse and have given insight to a potential mechanism of action of 
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menoctone. Further exploratory investigations would provide support towards whether 
menoctone may serve as a lead for novel antimalarial drug development. 
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Table 3.1. Single Dose Treatments Not Sufficient for Mutation Selection. Sensitive 
and resistant parasites were challenged with either menoctone or atovaquone at different 
concentrations to observe whether single dose treat was favored. Single rounds of drug 
are not sufficient to select for M133I point mutation and resulted in WT genotypes at 
cytb, identical to the parent strain, Pb luc ANKA. All menoctone resistant parasites 
demonstrated the M133I point mutation. Remarkably when genotyped, sporozoites 
produced from menoctone resistant blood stage parasites also carried the M133I point 
mutation, while sporozoites harvested from the sensitive parasite line displayed WT cytb. 
 
 
  
Parasite Nucleotide Mutation Genotype 
P. berghei luc ANKA (blood stages)  
+  
Atovaquone or Menoctone (single dose) 399 none WT 
P. berghei MEN-R (blood stages)  
+  
Atovaquone or Menoctone (single dose) 399 G->T M133I 
P. berghei luc ANKA (sporozoites) 399 None WT 
P. berghei MEN-R (sporozoites) 399 G->T M133I 
Pb MEN (MRA-414) 
(blood stages) 397 G->T M133L 
W2-MEN-R 
(blood stages)  399 G->C M133I 
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*: 0-50 oocysts= +; 51-100 oocysts = ++; 101-150 oocysts = +++, 151-200 oocysts = 
++++; > 200 oocysts = +++++ 
 
 
Table 3.2. Menoctone Resistance Point Mutation Capable of Mosquito 
Developmental Stage Transmission and Produces Next Generation Blood Stage 
Infection. Menoctone resistant point mutation was identified in pre-mosquito fed blood 
stage parasites. The blood meal produced positive oocysts and sporozoite infections in 
mosquitoes. Sporozoites produced next generation blood stage infection. M133I point 
mutation was fully maintained throughout the transmission in menoctone resistant 
parasites while the sensitive parasites demonstrated WT cytb. 
  
  
Pre-
mosquito 
Feed 
 
 
 
Post-mosquito Feed 
 
 
Mice post-sporozoite 
inoculation 
 
Parasite 
strain 
 
Cyt b 
Genotype 
No. 
infected 
midguts 
(%) 
 
Midgut 
infection 
score* 
 
Sporozoites 
per 
mosquito 
 
Cyt b 
Genotype 
Mice with 
patent 
infections 
(%) 
 
Cyt b 
Genotype 
Pb luc 
ANKA 
WT 37/50 
(74%) 
++ 21,071 WT 3/3 
(100%) 
WT 
Pb  
MEN-R 
 
M133I 
19/54 
(35.2%) 
 
+++ 
 
1,593 
 
M133I 
5/5 
(100%) 
 
M133I 
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Figure 3.1. Synthesis of Menoctone.  
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Figure 3.2. Menoctone and Atovaquone Efficacy Against P. berghei luc ANKA Liver 
Stages (A, B) and P. falciparum Blood stages In Vitro (C). 
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Figure 3.3. Generation of Menoctone Resistance in P. berghei luc ANKA. Blood from 
recrudescent infections was serially passaged in malaria naïve mice following treatment 
with 3 (A), 30 (B), and 300 mg/kg (C, D). Mice were treated on day 0 of the study and 3 
mice were used per group; data shown are the mean parasitemia of each group.  
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Figure 3.4. Survival Curves of Sensitive  (A, C) versus Menoctone Resistant 
P.berghei (B, D) Following Treatment with Menoctone or Atovaquone. Menoctone 
offers some protection to Pb luc ANKA infected mice (A), but demonstrates a marked 
decrease in protection against menoctone resistant parasites, Pb MEN-R (B). Atovaquone 
provided significantly more efficacy than menoctone (C), however even at the highest 
dose of 10 mg/kg, atovaquone was not effective at preventing recrudescence of Pb MEN-
R (D).  
 
  
Pb luc ANKA Pb MEN-R 
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Figure 3.5. Assessment of Atovaquone Cross-Resistance with Menoctone with P. 
berghei MEN (MRA-414).  P. berghei MEN infected mice were treated with atovaquone 
at 3 (A), 30 (B), and 100 mg/kg (C) on day 0 (n=2 per group). Parasitemia decreased to 
<1% parasitemia following atovaquone treatment after each treatment; however, 
atovaquone failed to completely clear all of the parasites after each round and low 
concentrations of parasites were observed. The confirmation of atovaquone cross-
resistance with menoctone resistant parasites was evident by failure to significantly 
eliminate asexual blood stage parasites with a subsequent dose of 100 mg/kg atovaquone. 
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Chapter Four 
 
Identifying and Understanding a New Potential Genetic Marker Conferring Resistance 
Against Plasmodium Infection 
 
Introduction 
Different Genetic Backgrounds Influenced by Malaria. Malaria is an infectious 
disease that has greatly impacted the progression of human genetics. Plasmodium falciparum has 
been and still remains a major cause of morbidity and mortality amongst humans, especially in 
endemic areas of sub-Saharan Africa (140). JBS Haldane first speculated that depending on the 
genetic makeup, people have different risks of dying when confronted by a parasitic organism. 
He used Darwinian selection to deduce that if the gene offered protection against the harmful 
parasite, then its frequency would increase when the population was exposed to the parasite 
(141). Later, this speculation became known as the “malaria hypothesis”. Time and 
advancements in science and technology bolstered Haldane’s hypothesis demonstrating how 
genetic factors from the human host contribute to the variability of malaria phenotypes, including 
hyper symptomatic and asymptomatic parasitemias, severe malaria anemia (SMA) and cerebral 
malaria (CM) (142). Genome wide linkage screening of many independent African villages, 
differing in ethnicity, also illustrated how malaria transmission and endemicity was linked to 
genetics. Several inter-ethnic comparative studies have shown that the Fulani population located 
in West Africa is more resistant to Plasmodium falciparum than other groups in Africa (143). 
The Fulani group’s increased resistance to P. falciparum malaria can be attributed to a functional 
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deficit in T-regulatory cells. The study results suggested that the T-regulatory cells are essential 
to malaria infection control in the population due to the naturally high transmission exposure the 
people endure daily. The authors believe that the higher resistance against malaria could be the 
driving force behind the T-regulatory cell deficiency disorder selection in that particular region 
of Africa. Molecular genetic approaches have proven that polymorphisms and several gene 
mutations in the human host confer survival advantages and have been selected over time. Some 
of the genetic polymorphisms that are associated with host phenotype susceptibility or resistance 
to P. falciparum include, but are not limited to, HLA-B, HLA-DRB1, TNFα, and IFNG. Many of 
these polymorphisms are fundamentally linked to host immunity, such as human leukocyte 
antigen system (HLA), and although the polymorphisms do not cause pathology for the host, 
expression is associated with malaria disease severity (144). Hemoglobinopathies also offer 
protection to the human host from malaria because the disorders decrease the parasites’ ability to 
invade red blood cells. Absence of the Duffy blood group, increased oxidative stress, and 
diseases such as sickle cell trait (HbAS), thalassemias, and G6PD have been shown to aid in 
human host resistance against the malaria parasite. Molecular biology techniques have aided in 
identifying how malaria susceptibility has been affected by immune response modulation 
through adaptation and how the malaria parasite has been affected through its co-existence with 
its human host.  
  Sickle Cell Disease. Sickle cell disease (SCD) describes a group of inherited red 
blood cell disorders. SCD patients have abnormal hemoglobin, which is characterized by red 
blood cells displaying a sickle-like shape. Some forms of SCD include: hemoglobin SS, SC, Sβ0 
thalassemia, Sβ+ thalassemia, SD, and SE. Normal red blood cells contain normal disc shaped 
hemoglobin, which allow for the RBC to take up oxygen in the lungs and carry it to all the other 
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tissues in the body. The disc shape is flexible and is able to move through the blood vessels 
easily. However, SCD hemoglobin is stiff and crescent or sickled-like shapes which causes the 
cell to have difficulty carrying oxygen. The irregular shape tends to stick to vessel walls and may 
slow down or stop the flow of blood, which further decreases the oxygenation of tissues in the 
body. This lack of oxygen to local tissue may cause sudden attacks of severe pain known as 
sickle cell crisis. Prolonged periods of crisis may cause life long damage to the human spleen, 
brain, liver, lungs, eyes, heart, and kidneys. The lack of flexibility of the crescent-like RBCs 
increases hemolysis of the diseased RBCs, causing anemia in patients. Sickle cell anemia (SCA) 
is a homozygous recessive genetic disorder, meaning the patient inherited two copies of the 
abnormal gene, and thus displays phenotypic disease characteristics. The two abnormal copies 
causes the person to produce hemoglobin SS instead of normal hemoglobin. If left untreated, SS 
reduces life expectancy greatly. Heterozygous patients (HbAS), also known as sickle cell trait, 
inherit one abnormal copy of the gene from one parent a normal copy of the gene from the other 
parent, and thus these people are normal for most purposes and live a normal life. People who 
are heterozygotes for sickle cell anemia are protected against severe malaria (SM) (145-147). AC 
Allison performed Haldanes’ hypothesis, and the studies showed that the sickle gene was 
frequent in areas of high malaria transmission along with G6PD deficiency.  Allison also 
demonstrated that AS heterozygotes seemed to have less malaria (148). The mechanism of 
protection against malaria is unclear, however, it is believed that parasites invading the RBC 
causes sickling of the cell, and thus increases the chances of the infected cell to be phagocytized. 
In 2004, Ayi et al confirmed the increased rate of phagocytosis of parasite-infected HbAS red 
blood cells (149) further bolstering the theory that sickle cell trait offers a form of protection 
 96 
against malaria. SCD is a unique phenomenon that illustrates the influence of malaria exposure 
in the evolution of human immunity. 
  Thalassemia. Similar to SCD, thalassemia is a genetically inherited blood 
disorder that is prevalent in malaria endemic regions of Sub-Saharan Africa. β-thalassemias are 
characterized by a deficiency of β-globin chains and contain molecular defects. Mutations that 
completely inactivate the β gene, which result in no β-globin production, cause what is known as 
β0-thalassemia. Depending on the reduction of β-globin production, the designation of β+ and β++ 
are used for different mutations of the β gene. The reduction of the β globin results in an excess 
of α-globin accumulation, which is the culprit behind the pathophysiology seen in this disorder. 
The severity is related to the degree of imbalance between α-globin and non-α–globin chain 
synthesis and the amount of free α–chain available. This is determined by the severity of the β 
allele mutation. In most cases, β-thalassemias are dominantly inherited; however, interestingly in 
malaria-endemic regions, the recessive from of β-thalassemia is more common. In the 1950s 
epidemiological studies on hemoglobin S in Africa provided evidence supporting the “malaria 
hypothesis” but has proved challenging to verify the hypothesis for thalassemias until recent 
years. Molecular genetic analyses of populations in the Pacific southwest with α-thalassemia and 
malaria show indisputable evidence that thalassemias provide protection against malaria (150). 
The protection is consequent of heightened susceptibility toward P. falciparum and P. vivax in 
very young children, however this early exposure offers superior protection against malaria later 
in life. 
  Ovalocytosis. Also known as Southeast Asian Ovalocytosis (SAO), ovalocytosis 
is a primary example of how malaria has played a role in adapting human genetics to protect 
itself from the parasitic infection in malaria endemic regions of Southeast Asia. SAO is caused 
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by a heterozygous 27-nucleotide deletion on the SLC4A1 coding for band 3, which is the anion-
exchange protein located on the red blood cell (151).  Erythrocytes affected by the deletion have 
reduced susceptibility to parasite invasion (152). Although the mechanism of the inhibition is 
unclear, it is believed that changing the binding of band 3 to parts of the cytoskeleton limits the 
redistribution of the protein that is normally seen when the parasites tries to invade (153). It is 
believed that this protective mechanism has been selected in Southeast Asian populations to 
protect the people from malaria; however, further studies need to be conducted to prove the 
strong associations seen between SAO and protection against P. vivax. 
Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD). G6PD affects over 
400 million people worldwide and it is generally a non-fatal disease on its own unless the patient 
is exposed to exogenous agents such as fava beans and antimalarial drugs like primaquine. G6PD 
is an x-linked genetic disorder that is mostly asymptomatic. Located on the X-chromosome at the 
q8 locus, the G6PD gene is 18kb long, containing 13 exons (154, 155). There are many 
polymorphisms of the G6PD gene and G6PD deficiency is mainly caused by single point 
mutations, insertions, and deletions. Over 200 variant alleles have been described and 140 
variants have been characterized through the use of PCR.  Phenotypically, G6PD deficiency is 
presents in hemizygous males, while heterozygous females will display partial deficiency 
characteristics. There are currently only two methods for diagnosing G6PD deficiency. For men, 
the fluorescent spot test is recommended, but the test only discriminates between hemizygous 
G6PD-deficient men from non-deficient men. On the other hand, for women, a cytochemical 
assay is recommended. This assay is difficult to perform and expensive, which is not ideal for 
developing and third world countries where the disorder mainly exists. Deficient patients suffer 
from hemolytic anemia. Within cells, nicotinamide adenine dinucleotide phosphate (NADPH) 
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offers protection against reactive oxygen species (ROS) and it is normally regenerated by G6PD 
during times of high oxidative stress. Reduced glutathione (GSH) is essential for free radical 
detoxification. Glutathione metabolism is highly dependent on the oxidation of glutathione to its 
disulfide form and then recycling of the molecule to its reduced form by the co-enzyme NADPH 
through the mediation of glutathione reductase. G6PD is the key enzyme in the oxidative pentose 
phosphate pathway, which converts NADP+ to its reduced form, NADPH. However, for those 
suffering from G6PD deficiency, this important process is impaired and cells are exposed to 
abnormally high levels of free radicals, which increases the amount of oxidative damage incurred 
by the cell. Most cells have other methods of obtaining NADPH in order to decrease oxidative 
damage from ROS, but this is not an option for erythrocytes. During the aging process of an 
erythrocyte, the amount of G6PD decreases significantly, thus making red blood cells more 
vulnerable to insults of oxidative stress. Developed erythrocytes lack a nucleus, mitochondria 
and ribosomes, thus they are unable to synthesize new proteins (156). Since G6PD deficient 
patients have a poorly functioning oxidative pentose phosphate pathway, all cells are able to 
compensate for the lack of G6PD except erythrocytes. Since erythrocytes are not capable of 
synthesizing proteins de novo, G6PD is not transcribed nor translated, and thus not able to 
protect the erythrocyte from increasing levels of oxidative stress. G6PD deficiency related 
hemolysis occurs when oxyhemoglobin reacts to form a superoxide that decomposes to hydrogen 
peroxide. The peroxide accumulates, causing hemoglobin denaturation and binding to the cell 
membrane. The inclusions within the red blood cells composing of the denatured hemoglobin are 
known as Heinz bodies. Hemolysis occurs when the erythrocytes enter the spleen, the Heinz 
bodies are removed by destroying the red blood cell, and eventually causing anemia. Thus, 
patients suffering from G6PD deficiency are more vulnerable to elevated levels of oxidative 
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stress and hemoglobin denaturation occurs more readily. However, evolution has selected this 
disorder in malaria endemic countries to provide resistance against severe malaria. Several field 
clinical studies performed in East and West Africa have shown that children with G6PD 
deficiency suffer less from severe malaria and have lower parasitic load than children without the 
disorder. The amount of protection is unknown however, two large case studies of over 2,000 
African children showed that the common African form of G6PD (G6PD A-) is associated with a 
46-58% reduction in risk of severe malaria for both female heterozygotes and male hemizygotes 
(157). 
Duffy Blood Group Negative. A standard example of genetic-based immunity 
showing the influence that malaria has played on the human host is the resistance to P. vivax by 
many Central and West African natives. These people lack the expression of the Duffy antigen. 
The Duffy antigen is a chemokine receptor (DARC), also known as Fy glycoprotein or Cluster of 
Differentiation 234 (CD 234) that is encoded by the DARC gene in humans and located on the 
long arm of chromosome 1. The receptor is located on the surface of the red blood cell and the 
blood group is named after the patient in which it was discovered. It is a single copy gene 
covering over 1500 bases and encodes for a 336 amino acid glycoprotein, controlling the 
expression of antigenic determinants of the Duffy blood group. There are two co-dominant 
alleles: FY*A and FY*B result from a G44D and a T-to-C mutation in the GATA box of the Fy 
promotor region. FY*A allele arose in South East Asia and confers partial resistance to clinical 
P. vivax infection (158). FY*B allele is predominantly found in sub-Saharan African populations 
(159). Duffy antigens act as a receptor for invasion by malaria parasites P. vivax. Researchers 
showed that Duffy negative individuals, whose red blood cells do not express the receptor, were 
able to resist merozoite invasion (160). Invasion requires two separate but integral stages: first, 
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the merozoite must recognize, attach, and orient itself to the erythrocyte surface, then forming 
junctions through which the parasites enter the cell (161). The second step is where Duffy 
antigens are of importance. A 35-amino acid segment of the Fy6 domain of the glycoprotein 
interacts with the Duffy binding protein, which is produced by the merozoite’s micronemes 
(162). Fy negativity in the co-dominant alleles prevents the binding of the erythroid transcription 
factor, GATA-1(163). Homozygosity for this trait is unique to populations living in the tropical 
areas of Africa, which supports the lack of P. vivax infections seen in African Americans (164). 
ABCG2 Efflux Transporters Export Extra- And Intracellular Molecules. ABCG2, 
also known as the ATP-binding cassette sub-family G member 2, are membrane-bound proteins 
that are encoded by the ABCG2 gene in humans. These proteins are generally located on the 
membranes of many uptake and excretory organs and at protective barriers where they are 
responsible for the export of endogenous and xenobiotic compounds and successfully export 
compounds even against extreme concentration gradients. The ABC genes are divided into seven 
subfamilies which include: ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White. In 
particular, ABCG2 is a member of the White subfamily, which is also referred to as BCRP, 
breast cancer resistance protein. BCRP functions as a xenobiotic transporter which had been 
hypothesized to play a role in multidrug resistance to cancer chemotherapeutic agents including 
mitoxantrone as well as malaria chemoresistance. These transport proteins are effective at 
protecting organisms from potentially toxic drugs through their excretion mechanism, which 
decreases the intracellular concentrations of compounds. BCRP expression has been detected in 
the placenta and seems to have a role in providing protection against drugs in the maternal 
circulation for the developing fetus (165). While not much is known about antimalarial 
compounds and direct interaction of ABC transporters, there are indications of possible effects of 
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p-glycoprotein mediated antimalarial export following exposure to many of the antimalarial 
compounds, including chloroquine, artemisinin and primaquine to name a few. The emergence 
of antimalarial resistance has also been linked to a major multi-drug transporter in mammalian 
cells known as Plasmodium falciparum multidrug resistance protein-1 (pfmdr1), which is also a 
p-glycoprotein homolog. Studies using both clinical isolates as well as laboratory adapted strains 
have demonstrated a link between resistance against chloroquine and the expression of pfmdr1 
(166). These efflux transporters are pivotal towards protecting cells and organisms from toxic 
substances.  
Heme-oxygenase-1 and BCRP. Heme, a toxic byproduct released by the parasite as a 
result of the parasite digestion of the RBC, is known to increase permeation and increase 
destruction of the blood-brain-barrier (BBB) (167). Heme oxygenase-1 (HO-1) is a known 
primary heme-degrading enzyme, and has been shown to possess protective effects against 
severe forms of rodent malaria (148). HO-1 was first identified in 1968, and most of the studies 
of the time focused on the regulation and function of HO-1 in heme metabolism. HO-1 catalyzes 
the rate-limiting first step involved in heme degradation. It is encoded by the gene Hmox1, and 
increased expression is induced by heme-containing and non-heme substances such as 
prostaglandins, heat shock proteins, heavy metals, and inflammatory cytokines (168). In 2007, 
Mota et al demonstrated that the upregulation of HO-1 prevented the development of 
experimental cerebral malaria (ECM) by 83.5% when comparing Hmox1+/+ to Hmox-/- Balb/C 
mice (169). The same researchers also demonstrated that pharmacological induction of HO-1 or 
exposure to carbon monoxide (CO) reduced the disruption of the blood-brain-barrier (BBB) by 
80.2% by inhibiting the enlistment of CD8+ T cells to the brain, which has been shown to be 
critical in the pathogenesis of ECM. It has been shown that HO-1 generates carbon monoxide, 
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iron and biliverdin as byproducts; the carbon monoxide prevents the ROS mediated oxidation of 
hemoglobin to heme. The resulting lowered levels of heme decrease the permeability and 
destruction of the tight junctions of the BBB. Thus, the rise of carbon monoxide production 
increases the resistance of host cells against the cytotoxic effects produced by the malaria 
parasite. Furthermore, Wagener et al demonstrated that the overexpression of HO-1 and BCRP 
protected human embryonic kidney cells against heme-induced cytotoxicity (170). This finding 
suggests that BCRP WT (wild type) mice would be more resistant to malaria induced heme 
toxicity.  
Malaria parasites degrade host hemoglobin for amino acids and this process causes 
extensive hemolysis releasing toxic free heme. In order to protect itself, the parasite has 
developed mechanisms using polymerase to bind free heme into non-toxic crystals known as 
hemozoin. Protoporphyrin IX is a critical precursor to biologically essential prosthetic groups 
such as cytochrome c, chlorophylls and heme. Protoporphyrin IX (PPIX) has also been 
associated with coordinating hematin formation and it has been postulated that free PPIX may 
interfere with the formation of hemozoin. Normal erythrocytes possess zinc protoporphyrin 
(ZnPPIX) at low micromolar levels, but these levels elevate in anemias and iron deficient 
patients. Iron deficiency anemias have been associated with host protection against malaria, 
where ZnPPIX inhibits iron protoporphyrin (FePPIX) crystal formation, which protects the host 
from malaria (171). Other studies have also shown that the pharmacologic inhibition of HO 
enzymatic activity by ZnPPIX resulted in the death of 77.5% of infected, Hmox1+/+ Balb/C mice 
that showed ECM symptoms (169).  The study also demonstrated that ZnPPIX does not 
influence the parasitemia levels, suggesting that the HO-1 protection observed is not dependent 
on parasitemia inhibition. The researchers also revealed that mice treated with cobalt 
 103 
protoporphyrin (CoPPIX), a protoporphyrin inducing HO-1 expression and activity, failed to 
develop ECM. They believe that CoPPIX interferes with the parasite’s ability to polymerize the 
heme into hemozoin. Another source of host resilience has been linked to ferrochelatase, the 
enzyme responsible for converting PPIX into heme. Red blood cells produced by ferrochelatase 
gene (FECH) deficient patients have also demonstrated resistance against the cytotoxic effects of 
malaria infections (172). The resistance is due to an absence of FECH but not associated with 
excess PPIX substrate. The FECH deficiency results in lowered levels of toxic heme, which have 
also been associated with decreased disease severity and better survival. It has been shown that 
BCRP KO (knockout) mice have approximate normal levels of heme, despite the increased PPIX 
levels since FECH is the rate-limiting step in converting PPIX to heme. 
Scope of Study. There is still much to be learned about genetic alleles and the roles they 
play in the human host relationship and malaria evolution. In humans, there is an inactivating 
allele for BCRP and this allele is largely absent in populations located in sub-Saharan Africa. 
Interestingly, the inactivating allele is present in populations in East and South East Asian 
countries (Figure 4.1). We have used the FVB WT versus KO mice to model these genetically 
distinct groups of people. KO mice have normal FECH expression, which makes approximately 
normal levels of heme but have elevated PPIX, which will increase oxidative damage and 
inflammation due to increased production of ROS. We hypothesize that the increase in PPIX and 
or uric acid may increase the sensitivity to heme toxicity secondary to malaria parasite infection 
for the KO mice. In this study, we elucidate whether knocking out this allele is associated with 
an increase in malaria disease severity. It is only in areas where malaria is prevalent that this 
inactivating allele is observed, which suggests that BCRP may be another marker that has been 
selected for by malaria infections in people over time. 
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Materials and Methods 
Parasite Growth and Mice Inoculation. This study was conducted twice, first with 
Plasmodium berghei berghei and validated with Plasmodium vinckei vinckei. Both parasites 
were first inoculated into Balb/C mice (EnVigo Laboratory, Indianapolis, IN) to ensure its 
successful growth. Once parasitemia was established to approximately 4%, the mice were 
humanely euthanized and subsequently underwent cardiac puncture to obtain parasitized blood. 
The parasitized blood was then diluted to 1% parasitemia per 150 µL and injected into FVB 
donor mice. Two donor mice were allowed to reach approximately 30% parasitemia before 
cardiac blood was collected and the mice were euthanized. Parasitemia was determined by 
dividing the number of infected red blood cells (iRBCs) by the total number of RBCs present per 
field, then multiplied by 100 to calculate the percentage parasitized. Each experimental mouse 
was inoculated with 106 parasites. In order to calculate the total volume of iRBCs needed to 
inoculate each mouse with the correct amount, the total number of RBCs in the sample was 
determined. An aliquot of parasitized mouse blood was then counted for total number of RBCs 
present and multiplied by the percent parasitemia. This value indicated the number of infected 
RBCs in our sample. Each mouse was then inoculated by IP injection at 100 µL per mouse. FVB 
donor mice were allowed free-choice mouse pellets and water. Tail vein blood smears were 
taken to monitor parasitemia on days 3, 5, 6, 7 and then daily until day 30 or before the end of 
the study. If mice reached 40% parasitemia, they were humanely euthanized and one last blood 
smear was taken. In addition, if a mouse was suddenly found dead, a blood smear sample was 
attempted for potential data collection (Figure 4.2). This study was conducted in compliance 
with the Guide for the Care and Use of Laboratory Animals of the National Research Council for 
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the National Academies. The protocol was approved by the University of South Florida 
Institutional Animal Care and Use Committee.  
 
Results 
 FVB Mice Display Later Onset of Infection Than KO Mice in P. berghei berghei 
infection. On day three of the study, FVB mice displayed a higher starting parasitemia when 
compared to the KO mice when infected with P. berghei luc ANKA. Although the FVB group 
started off with a higher parasitemia than the KO counterparts, the parasite growth in the FVB 
mice was not as robust as the KO group. On day 13 of the study, the KO mice continued to 
increase in parasitemia rapidly while the FVB group maintained steady parasite growth (Figure 
4.3). Survival curves for FVB versus KO mice indicate that FVB had a delayed onset of parasites 
in the peripheral blood than KO mice; however, both groups succumbed to the disease on the 
same day. 
 FVB Mice Survive Plasmodium vinckei vinckei Challenge. When challenged with P. 
vinckei vinckei, FVB mice failed to develop blood stage parasitemia while the KO group 
presented blood stage parasites by day seven into the study. All FVB mice survived the 30 study 
and none of the mice developed blood stage parasites; however, in the KO group the majority of 
the mice succumbed to the infection by day eight of the study and had to be euthanized due to 
overt parasitemia. All KO mice perished from the parasitic disease except for three mice, which 
survived until day 30 and failed to develop parasites (Figure 4.4). 
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Discussion  
 FVB Allele Imparts Protection Against Murine Malaria. Over time, the co-existence 
of the malaria parasite with the human host has selected for certain genetic mutations that 
imparts protection for humans against the deadly parasite. Classic examples of this natural 
selection include sickle cell disease, Southeast Asian ovalocytosis, thalassemias, G6PD and 
Duffy group negative populations in West Africa. These examples all bolster our hypothesis that 
the FVB allele might be another example of genetic mutations conferring resistance against 
malaria infection. 
 In this study, we demonstrated for the first time how the FVB allele imparts immunity 
against severe murine malaria infection development. When challenged with P. berghei berghei, 
both FVB and FVB KO mice developed blood stage infection by day three. Even though the 
FVB mice all initially started with a higher average parasitemia count when compared to the KO 
group, the parasites replicated steadily in the FVB mice while the KO mice developed overt 
parasitemia shortly after the study began. Survival analysis of the FVB versus KO mice when 
infected with P. berghei demonstrated that the KO mice succumbed to infection a day earlier 
than their FVB complements. Both groups perished by day 16 of the study, as confirmed by tail 
vein blood smears that overt parasitemia was the cause of death. Both Mantel-Cox and Wilcoxon 
statistical analysis tests showed that the FVB allele does not have statistical significance for 
imparting protection against murine malaria, p-value 0.892 and 0.446, respectively. 
 Perhaps the most remarkable results we observed were when FVB mice were challenged 
against extremely virulent murine malaria parasite, P. vinckei vinckei. Asexual stage parasites 
were first observed on day seven of the study in the FVB KO mice group and parasitemia rose 
exponentially until day 14, which at the time resulted in all of the mice either passing or being 
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humanely euthanized due to extreme parasitemia levels. Interestingly, all of the FVB mice were 
protected and no mice from the FVB group developed parasites throughout the 30-day study. 
Statistical analysis using both Mantel-Cox and Wilcoxon statistical analysis tests showed 
statistical significance having p values of 0.005 and 0.006, respectively.  
 Our data confirmed that this genetic inactivation event that plays an important role in 
malaria disease severity. Our study shows that FVB expression protects mice from highly 
virulent rodent malaria infection. These results suggest that we may have identified another 
marker that has been selected by malaria infections in people over time. This allele is largely 
absent amongst populations in sub-Saharan Africa; however, the inactivating allele is present 
mainly in East and Southeast Asian populations, which may play a role in this population’s 
susceptibility to malaria. It is believed that the absence of the allele in Africa could be due the 
allele arising centuries ago in people who later migrated out of Africa. Another theory postulated 
for the evolution of this allele is that it could have also been selected against over time. The 
second theory is supported by the data generated from the FVB KO versus FVB WT model that 
we present here in this study. 
 Identifying new genetic markers associated with malaria infections is a fundamental step 
towards defeating the deadly parasite. Understanding how the activation or inactivation of the 
FVB allele affects the disease process is extremely important in furthering our knowledge of 
malaria and how it affected genetic natural selection. The identification and confirmation of how 
the FVB allele affects malaria parasite development offers insight as to why populations in 
Southeast Asia have a higher propensity towards inheriting the inactivated allele. It is fascinating 
that the inactivating allele is only present in Southeast Asian populations where P. vivax is 
prevalent and not in Africa where P. falciparum kills droves of people yearly. Perhaps there may 
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be an underlying connection between P. vivax disease severity and the inactivation of the FVB 
allele in humans. The link discovered between FVB and parasite development also serves as a 
potential novel marker to identify a person’s susceptibility to malaria infection and offers many 
opportunities towards better understanding how malaria parasite burden selects for certain 
genetic changes in the human host over time. 
 
Conclusion  
 Malaria has played an important role in human genetics by influencing genetic mutations 
that increase host survival against malaria infection. G6PD deficiency, ovalocytosis, 
thalassemias, Duffy binding blood group, and sickle cell anemia are all classic examples of how 
human genetics have changed in order to co-exist with the protozoal parasite. Our studies show 
that the expression of the BCRP allele confers protection against severe malaria infection. The 
studies we performed illustrate groundbreaking research in this area of malaria research, but due 
to its infancy, not much is known about the mechanisms to how this allele protects people from 
malaria. Despite this fact, we believe that there is a dual mechanism by which this allele offers 
protection against Plasmodium species. We hypothesize that HO-1 plays a vital role in increasing 
host resistance against cytotoxic heme from the destruction of the BBB as well as other vital 
tissues meanwhile, BCRP transports PPIX in a manner such that the parasite’s ability to 
polymerize heme into hemozoin decreases, thereby decreasing parasitemia. Nonetheless, our 
research has identified a new genetic marker that most likely has been selected for over time. 
This genetic marker may potentially allow us to assess the susceptibility an individual or a 
population has to malaria. Further, genetic studies on people with known BCRP alleles or 
deletions and their sensitivity to malaria infections in Southeast Asia are required to investigate 
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our findings. Hopefully, our discovery will someday help identify people with increased risk for 
malaria infection and thus take extra preventative measures to protect them from contracting and 
spreading the parasitic disease. 
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Figure 4.1 BCRP Allele Frequency and Distribution. In humans, ABCG2 has an inactivating 
allele, which is demonstrated in yellow. This allele is largely absent in sub-Saharan Africa, 
indicated in blue. It is strangely absent in Sardinia, which was one of the places of highest 
malaria prevalence until the post-WWII era. The inactivating allele is present mainly in East 
Asian populations. 
 
*Source: Erin Schuetz, Ph.D. St. Jude Children’s Research Hospital (Memphis, TN); used with 
permission. 
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Figure 4.2 Parasite Growth and Mice Inoculation. P. berghei luc ANKA or P. vinckei-vinckei 
was injected intraperitoneally into FVB or FVB KO mice on day 0. Mice tail vein blood smears 
were monitored on days 3,5,6,7,8,9,10,11,12…daily until day 30 of the study for parasite 
development. If the animals were moribund or developed parasitemia levels >40%, one last tail 
vein smear would be taken before the mouse was humanely euthanized.  
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Figure 4.3. FVB Mice Display Later Onset of Infection than KO Mice in P. berghei-berghei 
infection. FVB mice displayed a higher parasitemia initially while the KO group presented with 
lower parasitemia levels. On day 12 of the study, the FVB mice steadily climbed in parasitemia 
counts while the KO mice surpassed the FVB group in parasitemia. The Mantel-Cox, and Gehan-
Breslow-Wilcoxon test both showed no statistical significance between the FVB and KO mice 
groups. 
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Figure 4.4. FVB Mice Survive Plasmodium vinckei-vinckei Challenge. When challenged with 
P. vinckei-vinckei, the FVB mice were protected against the highly virulent parasite, while the 
KO mice all developed parasites except for a few lone survivors, which did not develop parasites 
even at the end of the study on day 30. The KO mice presented with parasitemia on day 7 and 
continued to increase in parasitemia until day 30, while the FVB mice all failed to develop 
parasites. The Mantel-Cox and Gehan-Breslow-Wilcoxon tests verify that there is statistical 
significance between the FVB and KO groups infected with P. vinckei. 
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Chapter Five 
 
Conclusions 
 
Summary of Findings 
 Malaria remains a significant global health concern that only affects third world 
countries, but threatens developed countries as well due to the vector remaining at large. This 
morbid disease has no licensed vaccine and only one drug is currently approved by the FDA to 
eliminate the dormant liver stage forms. In order to eradicate malaria, there are requirements that 
must be met for compounds to progress to the next stages of drug development. These 
requirements include: 
1. Fast clearance of blood stage parasites; reducing the initial parasite burden  
2. Ability to partner with a drug that has a long half life to complete clearance of blood 
stage parasites 
3. Targets hypnozoites 
4. Transmission blocking 
5. Single dosage 
6. No cross-resistance 
7. Good oral solubility 
8. Stable; does not require special care and storage conditions 
9. Clinically safe, efficacious and non-cytotoxic 
10. Affordable 
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In order to find a compound with these requirements, we first developed a high-
throughput drug assay that could screen large chemical libraries for blood stage active 
compounds. We identified and optimized cell seeding densities and sporozoite seeding densities 
to create an assay that produced robust results while decreasing the amount of material waste. 
The result was a 384-well liver stage assay that produced robust, accurate, and reproducible IC50 
values that used the same amount of materials as needed for the same assay in a 96-well plate. 
Our HTS tested over six times the amount of compounds and produced four times the amount of 
data when compared to the 96-well assay. Repeating our drug assay on multiple well 
characterized drug compounds highlighted the strong reproducibility and high precision of the 
HTS we developed. We expanded our testing compound library and showed that our drug assay 
was capable of testing compounds from different sources and chemical scaffolds, showing that it 
and it was not limited to testing only one drug class. Eventually, the development of the 384 well 
HTS drug screen allowed high profile facilities such as St. Jude Children’s Research Hospital, 
Manetsch Laboratory, and University of Central Florida to send us promising compounds to test 
for liver stage efficacy. The liver stage screen results were recently published as a collaborative 
effort in the Journal of Medicinal Chemistry. Another manuscript involving our liver stage 
screen describes the development of new promising piperazine-substituted antimalarial drug 
candidates is in its pre-submission phases. Lastly, a third manuscript, discussing the discovery of 
novel 8-AQ fluorescent probes studying the localization of primaquine and tafenoquine, also 
utilized our HTS liver screening assay for their scientific endeavors. 
The HTS liver stage assay eventually led us towards studying an old abandoned 
compound known as menoctone. Interest in studying this compound sparked from the fact that 
menoctone shares an identical core structure as the FDA approved antimalarial atovaquone. 
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Clarification on how menoctone affects the parasite allowed us to better understand how drugs 
with unknown mechanisms of action displaying similar structures target parasite development 
and life cycle. We demonstrated that atovaquone and menoctone select for the same point 
mutation in malaria parasites after prolonged exposure to the compound and theorized that 
perhaps other compounds of its class may act in a similar manner. Recently an Australian group 
of scientists published in Science presenting their findings that atovaquone resistance mutations 
were not capable of transmission through the mosquito vector. The results from our menoctone 
resistance study verified that the identical point mutation was transmittable through the same 
mosquito vector. The results from our work suggest that perhaps atovaquone resistance may still 
be transmittable through Anopheles mosquitoes. 
As an extra project performed during this dissertation, we reported on a new potential 
genetic marker that may identify an individual’s ability to resist malaria infection. The 
inactivating allele is present in populations located in East and South East Asian countries, but is 
largely absent in populations residing in sub-Saharan Africa. Our experiments indicated that 
mice, thus extrapolating to people, who express this allele, are protected from malaria infection 
and the secondary effects caused by the disease. Currently, the inactivating allele is only 
observed in areas where malaria is prevalent, which suggests that BCRP may be another marker 
that has been selected for by malaria infections in humans over time. Field studies with 
collaborators in Singapore and Japan are underway to identify people who have these KO alleles 
in order to further investigate how parasite development is affected in human subjects. 
In summary, these studies have led to several significant advancements in malaria 
research which include, the development of a new HTS liver stage drug screening assay, a 
clearer understanding of the mechanisms of action of abandoned compounds with similar core 
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scaffolding, and the identification of a possible new genetic marker in malaria resistance. The 
developments from our studies significantly increased the number of liver stage active 
compounds identified, which increased the number of novel antimalarials that will now undergo 
medicinal chemistry manipulations to enhance bioavailability and stability and eventually be 
used in the field to eliminate malaria. This work has also proved that mutations conferring 
resistance are indeed transmittable by the mosquito vector, and that more studies must be 
conducted to better understand how transmission of parasite mutations take place such that we 
can prevent this occurrence. Last, the identification of a potential new genetic marker allows for 
us to understand how evolution has selected for certain genetic backgrounds to withstand 
parasite burden over time and how certain populations possess an advantage against the deadly 
parasitic protozoan disease that still threatens our world today. The eradication of malaria 
remains a great challenge for the international community, and our work has brought us one step 
closer towards making malaria a disease that someday will only be known in history books. 
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